document incorporate reference portion abbvie inc proxy statement incorporate reference iii definitive proxy statement file march item business separation abbott laboratories abbvie incorporate delaware april january abbvie independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder abbvie common stock begin trade regularway ticker symbol abbv new york stock exchange january overview abbvie global researchbase biopharmaceutical company abbvie develop market advanced therapy address world complex disease abbvie product focus treat condition chronic autoimmune disease rheumatology gastroenterology dermatology oncology include blood cancer virology include hepatitis c hcv human immunodeficiency virus hiv neurological disorder parkinson disease metabolic disease include thyroid disease complication associate cystic fibrosis health condition abbvie pipeline promise new medicine include compound indication clinical development important medical specialty immunology virologyliver disease oncology neurological disease woman health abbvie complete acquisition pharmacyclics inc biopharmaceutical company develop commercialize novel therapy people impact cancer flagship asset imbruvica highly effective treatment hematologic malignancy approximately billion consist cash consideration billion equity consideration billion segment abbvie operate business segmentpharmaceutical product incorporate reference note entitle segment geographic area information note consolidated financial statement include item financial statement supplementary data sale information relate humira include item management discussion analysis financial condition result operationsresult operation product abbvie portfolio product include broad line therapy address world complex disease text report term abbvie refers abbvie inc delaware corporation abbvie inc consolidate subsidiary context require humira humira adalimumab biologic therapy administer subcutaneous injection approve treat follow autoimmune disease united states canada mexico collectively north america european union condition principal market rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylose spondylitis north america european union crohn disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthropathy united states european union pediatric crohn disease severe united states european union hidradenitis suppurativa united states european union pediatric enthesitisrelate arthritis european union humira approve market include japan china brazil australia humira introduce market january humira abbvie large product account approximately percent abbvie total net revenue united states composition matter compound patent covering adalimumab sell trademark humira expect expire december equivalent european union patent expect expire majority european union country october addition united states noncomposition matter patent cover adalimumab expire early abbvie continue dedicate substantial research development effort expand indication humira include field rheumatology gastroenterology pediatric ulcerative colitis ophthalmology uveitis regulatory application uveitis file united states abbvie continue work humira formulation delivery enhancement improve convenience overall patient experience imbruvica imbruvica ibrutinib firstinclass oral oncedaily therapy inhibit protein call bruton tyrosine kinase btk imbruvica currently approve treatment patient chronic lymphocytic leukemia cll receive prior therapy cll patient del p patients waldenstrm macroglobulinemia imbruvica approve treatment patient mantle cell lymphoma mcl receive prior therapy accelerate approval grant mcl indication base overall response rate continue approval indication contingent verification clinical benefit confirmatory trial imbruvica medicine receive food drug administration fda approval grant breakthrough therapy designation imbruvica therapy receive separate designation hcv product viekira pak ombitsavir paritaprevir ritonavir tablet dasabuvir tablet alloral shortcourse interferonfree therapy ribavirin treatment adult patient genotype chronic hcv include compensate cirrhosis viekira pak approve fda december europe abbvie hcv treatment market viekirax exviera approve use patient genotype genotype hcv european commission grant marketing authorization treatment january july fda approve abbvie technivie ombitasvir paritaprevir ritonavir use combination ribavirin treatment adult genotype hcv infection united states additional virology product abbvie additional virology product include kaletra norvir treatment hiv infection synagis prevention respiratory syncytial virus rsv infection high risk infant kaletra kaletra lopinavirritonavir market aluvia emerge market prescription antihiv medicine contain protease inhibitor lopinavir ritonavir kaletra antihiv medication treatment maintain viral suppression people hiv norvir norvir ritonavir protease inhibitor indicate combination antiretroviral agent treatment hiv infection synagis synagis palivizumab product market abbvie outside united states protect atrisk infant severe respiratory disease cause rsv metabolicshormone product metabolic hormone product target number condition include testosterone deficiency exocrine pancreatic insufficiency hypothyroidism product include androgel androgel testosterone gel testosterone replacement therapy male diagnose symptomatic low testosterone available strength percent percent creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occur patient cystic fibrosis chronic pancreatitis condition synthroid synthroid levothyroxine sodium tablet usp treatment hypothyroidism abbvie right sell androgel creon synthroid united states endocrinology product lupron levprolide acetate market lucrin lupron depot product palliative treatment advance prostate cancer treatment endometriosis central precocious puberty preoperative treatment patient anemia cause uterine fibroid lupron approve daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection product abbvie product include follow duopa duodopa carbidopa levodopa abbvie levodopacarbidopa intestinal gel treatment advanced parkinson disease market duopa united states duodopa outside united states anesthesia product sevoflurane sell trademark ultane sevorane anesthesia product abbvie sell worldwide human use dyslipidemia product abbvie dyslipidemia product tricor fenofibrate trilipix fenofibric acid niaspan niacin extend release address range metabolic condition characterize high cholesterol andor high triglyceride zemplar zemplar paricalcitol product sell worldwide treatment secondary hyperparathyroidism associate stage chronic kidney disease ckd research development activity abbvie numerous compound clinical development include potential treatment complex lifethreatening disease abbvie ability discover develop new compound enhance company use integrate discovery development project team include chemist biologist physician pharmacologist work compound team research development process generally begin discovery research focus identification molecule desire effect give disease preclinical testing identify compound prove successful compound move clinical development generally include follow phase phase involve human test small number healthy volunteer patient assess safety tolerability potential dosing phase test drug efficacy disease relatively small group patient phase test drug demonstrate favorable result early phase significantly large patient population demonstrate efficacy safety base regulatory criterion clinical trial development phase provide datum require prepare submit new drug application nda biological license application bla submission regulatory approval fda similar government agency outside united states specific requirement eg scope clinical trial obtain regulatory approval vary different country geographic region research development process discovery new drug launch typically take year long research development new pharmaceutical product significant inherent uncertainty guarantee molecule receive regulatory approval require launch new drug indication addition development new product new formulation research development project include phase trial call postmarkete study project clinical trial design conduct collect additional datum parameter benefit risk approve drug abbvie spend approximately billion billion billion research discover develop new product indication process improve exist product process expense consist primarily salary relate expense personnel license fee consulting payment contract research clinical drug supply manufacturing cost laboratory equipment facility clinical trial cost collaboration fee expense intellectual property protection regulatory exclusivity generally approval product entitle certain kind exclusivity applicable intellectual property regulatory regime abbvie seek patent protection available significant market andor country product development united states expiration date patent file june year filing date give patent relate pharmaceutical product obtain early development process give time need complete clinical trial development activity require regulatory approval length time product launch patent expiration significantly year drug price competition patent term restoration act commonly know hatchwaxman act permit patent holder seek patent extension commonly call patent term restoration patent product process make product regulate federal food drug cosmetic act length patent extension roughly base percent period time file investigational new drug application compound submission nda compound plus percent time period nda submission regulatory approval extension exceed year patent term remain regulatory approval exceed year pharmaceutical product entitle form legal regulatory exclusivity approval scope length requirement exclusivitie vary united states jurisdictions united states fda approve drug product contain active ingredient previously approve product typically entitle year nonpatent regulatory exclusivity product entitle year exclusivity approval base fda reliance new clinical study essential approval submit nda applicant nda applicant study product use child fda grant pediatric exclusivity extend day long exist exclusivity patent regulatory relate product product treat condition afflict relatively small population reasonable expectation research development cost recover fda designate pharmaceutical orphan drug grant seven year market exclusivity applicable law regulation dictate scope exclusivity product entitle approval particular country certain instance regulatory exclusivity protect product patent protection long available period time excess patent protection possible estimate product development total period scope exclusivity entitle regulatory approval obtain give length time require complete clinical development pharmaceutical product minimum maximum period exclusivity achieve individual case expect exceed year respectively estimate consider factor difficulty recreate manufacturing process particular product proprietary knowledge delay introduction generic followon product expiration applicable patent regulatory exclusivity period biologic entitle exclusivity biologic price competition innovation act pass march title vii patient protection affordable care act law provide pathway approval biosimilar follow expiration year exclusivity innovator biologic potential additional dayextension term conduct pediatric study biologic eligible orphan drug exclusivity discuss law include extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability prior approval biosimilar european union create pathway approval biosimilar publish guideline approval certain biosimilar product complex nature biologic biosimilar product lead great regulatory scrutiny rigorous requirement approval followon biosimilar product small molecule generic pharmaceutical product european union reduce effect biosimilar sale innovator biologic compare sale erosion cause generic version small molecule pharmaceutical product abbvie own license right substantial number patent patent application abbvie license own patent portfolio thousand patent family include united states patent application andor issue patent contain nonunite state counterpart patent application patent application include patent expire period late aggregate believe material importance operation abbvie business abbvie believe single patent license trademark relate group patent license trademark relate adalimumab sell trademark humira material relation company business united states composition matter compound patent cover adalimumab expect expire december equivalent european union patent expect expire majority european union country october united states noncomposition matter patent cover adalimumab expire early addition follow patent license trademark significant relate ibrutinib sell trademark imbruvica relate ombitasvirparitaprevirritonavir dasabuvir sell trademark viekira pak viekirax exviera holkira pak relate testosterone sell trademark androgel united states composition matter patent cover ibrutinib expect expire united states composition matter patent cover ombitasvir paritaprevir dasabuvir expect expire respectively abbvie rely circumstance trade secret protect technology trade secret difficult protect abbvie seek protect technology product candidate confidentiality agreement employee consultant advisor contractor collaborator agreement breached abbvie adequate remedy breach addition abbvie trade secret know independently discover competitor extent abbvie employee consultant advisor contractor collaborator use intellectual property own work company dispute arise right relate result knowhow invention market sale distribution capability abbvie utilize combination dedicate commercial resource regional commercial resource distributorship market sell distribute product worldwide abbvie direct primary marketing effort secure prescription recommendation brand product physician key opinion leader health care provider manage care provider example health maintenance organization pharmacy benefit manager hospital state federal government agency example united states department veterans affairs united states department defense important customer abbvie market directly consumer united states company product sell pursuant prescription outside united states abbvie focus marketing effort key opinion leader payor physicians country regulatory body abbvie provide patient support program closely relate product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse abbvie business significant seasonality abbvie product revenue affect end customer retail buying pattern fluctuation wholesaler inventory level factor united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie patient wholesale distributor mckesson corporation cardinal health inc amerisourcebergen corporation account substantially abbvie sale united states individual wholesaler account great percent abbvie gross revenues united states outside united states sale directly customer distributor depend market serve wholesaler purchase product abbvie standard term condition sale certain product comarkete copromote company abbvie single customer customer lose material adverse effect company business material portion abbvie business subject renegotiation profit termination contract election government order generally fill current basis order backlog material abbvie business party agreement abbvie agreement party process development analytical service manufacture certain product abbvie procure certain product service limit number supplier case single supply source example filling package humira syrinx sell outside united states puerto rico perform single supplier different facility abbvie currently believe agreement material abbvie business substantially risk access facility abbvie maintain significant inventory humira syrinx reduce risk supply disruption syringefille packaging facility united states approve supply syrinx primary market outside united states puerto rico addition abbvie agreement party active pharmaceutical ingredient product manufacturing formulation development service fill finish packaging service transportation distribution logistic service certain product abbvie believe manufacture relate agreement material abbvie business substantially dependent individual agreement case abbvie maintain alternate supply relationship utilize undue disruption manufacturing process party fails perform contractual obligation abbvie maintain sufficient inventory product minimize impact supply disruption abbvie party certain collaboration arrangement discuss note license acquisition arrangement license acquisition activity note consolidated financial statement include item financial statement supplementary datum certain agreement abbott discuss item management discussion analysis financial condition result operationstransition abbott cost operate independent company source availability raw material abbvie purchase ordinary course business raw material supply essential operation numerous supplier world addition certain medical device component necessary manufacture abbvie product provide unaffiliated party supplier abbvie experience recent significant availability problem supply shortage forecast sale environmental matter abbvie believe operation comply material respect applicable law regulation concern environmental protection regulation federal state environmental law impose stringent limitation emission discharge environment manufacturing operation abbvie capital operating expenditure pollution control approximately million million respectively capital operating expenditure pollution control estimate approximately million million respectively abbott identify potentially responsible party investigation andor remediation location united states include puerto rico comprehensive environmental response compensation liability act commonly know superfund location transfer abbvie connection separation distribution abbvie party investigation remediations abbott engage remediation site transfer abbvie connection separation distribution cooperation environmental protection agency similar agency feasible predict certainty final cost relate investigation remediation activity abbvie believe cost expenditure maintain compliance applicable law regulation concern environmental protection material adverse effect company financial position cash flow result operation competition market abbvie product highly competitive abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete number antitnf product approve number disease state abbvie virology product compete protease inhibitor antihiv treatment search technological innovation pharmaceutical product significant aspect competition introduction new product competitor change medical practice procedure result product obsolescence price competitive factor addition substitution generic pharmaceutical product brand pharmaceutical product create competitive pressure abbvie product patent protection biosimilar competition abbvie biologic product affect approval followon biologic know biosimilar biologic add major therapeutic option treatment disease include therapy unavailable inadequate advent biologic raise complex regulatory issue significant pharmacoeconomic concern cost develop produce biologic therapy typically dramatically high conventional small molecule medication expensive biologic medication ongoing treatment chronic disease rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investment biologics infrastructure manufacture necessary produce biologic product significant investment market distribution sale organization activity limit number biosimilar competitor united states fda regulate biologics federal food drug cosmetic act public health service act implement regulation enactment federal health care reform legislation march provide pathway approval biosimilar public health service act approval process science biosimilar complex approval process science generic followon version small molecule product add complexity step need ensure safety efficacy biosimilar highly similar original biologic humira ultimate approval fda dependent factor include show biosimilar highly similar original product clinically meaningful difference original product term safety purity potency vitro characterization type datum ordinarily require application similarity include analytical datum study demonstrate chemical similarity animal study include toxicity study clinical study law require biosimilar condition use approve original biologic manufacturing facility meet standard necessary assure biosimilar safe pure potent furthermore law provide biosimilar product determine interchangeable consider substitutable original biologic product intervention health care provider prescribe original biologic product prove biosimilar product interchangeable applicant demonstrate product expect produce clinical result original biologic product give patient product administer patient safety risk potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product great risk original biologic product switch law beginning interpret implement fda result ultimate impact implementation mean likely subject substantial uncertainty year come european union pathway approval biosimilar exist product come market date mixed impact market share incumbent product significant variation product competitive product number competitive biologic brand product approve humira introduce gain modest share worldwide market abbvie continue face competitive pressure biologic orally administer product regulationdiscovery clinical development united states secure approval market new pharmaceutical product united states require substantial effort financial resource take year complete applicant complete preclinical test submit protocol fda commence clinical trial clinical trial intend establish safety efficacy pharmaceutical product typically conduct sequential phase phase overlap combine require clinical testing successful result submit fda form nda bla request approval market product indication fda review nda bla determine product safe effective intended use manufacturing compliant current good manufacturing practice cgmp nda bla receive approval applicant comply postapproval requirement example holder approval report adverse reaction provide update safety efficacy information comply requirement concern advertise promotional material activity quality control manufacturing procedure continue conform cgmp approval certain change manufacturing procedure finish product include nda bla approve fda fda periodically inspect manufacture facility assess compliance cgmp impose extensive procedural record keeping requirement addition condition approval fda require postmarkete testing surveillance assess monitor product safety efficacy commercialization require additional clinical trial patient registrie additional work chemistry manufacturing control postapproval regulatory obligation cost comply obligation expand future outside united states abbvie subject similar regulatory requirement outside united states abbvie obtain approval clinical trial application product applicable regulatory authority commence clinical trial marketing product approval requirement process country vary time require obtain approval long shorter require fda approval united states example abbvie submit marketing authorization european union centralize decentralize procedure centralize procedure mandatory approval biotechnology product pharmaceutical product provide single marketing authorization valid european union member state centralized procedure single marketing authorization application submit european medicine agency agency evaluate application make recommendation european commission make final determination approve application decentralize procedure provide mutual recognition individual national approval decision available product subject centralized procedure japan application approval new product pharmaceutical medical device agency pmda bridge study demonstrate nonjapanese clinical datum apply japanese patient require complete comprehensive review pmda report ministry health labour welfare approve deny application regulatory process emerge market continue evolve emerge market include asia generally require regulatory approval obtain large develop market united states europe country begin complete regulatory review process country require local clinical study conduct order obtain regulatory approval country requirement govern conduct clinical trial product licensing vary addition postapproval regulatory obligation adverse event report cgmp compliance generally apply vary country example marketing authorization grant european union periodic safety report submit pharmacovigilance measure require risk management plan regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie product subject comprehensive government regulation government regulation national regional federal state local agency united states country address matter inspection control research laboratory procedure clinical investigation product approval manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarkete surveillance record keeping storage disposal practice abbvie operation affect trade regulation country limit import raw material finish product law regulation seek prevent corruption bribery marketplace include united states foreign corrupt practice act united kingdom bribery act provide guidance corporate interaction government official require safeguard protection personal datum addition abbvie subject law regulation pertain health care fraud abuse include state federal antikickback false claim law united states prescription drug manufacturer abbvie subject taxis application product user establishment fee compliance law regulation costly materially affect abbvie business effect health care regulation substantially increase time difficulty cost incur obtain maintain approval market newly develop exist product abbvie expect compliance regulation continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement action seizure recall product suspension revocation authority necessary product production sale civil criminal sanction include fine penalty addition regulatory initiative abbvie business affect ongoing study utilization safety efficacy outcomes health care product component regularly conduct industry participant government agency study question utilization safety efficacy previously market product case study result future result discontinuance limitation marketing product domestically worldwide rise claim damage person believe injure result use access human health care product continue subject investigation action governmental agency legislative body private organization united states country major focus cost containment effort reduce health care cost private sector notably health care payor provider institute cost reduction containment measure abbvie expect insurer provider continue attempt reduce cost health care product outside united states country control price health care product directly indirectly reimbursement payment pricing coverage limitation compulsory license budgetary pressure united states country heighten scope severity pricing pressure abbvie product foreseeable future united states specifically federal law require pharmaceutical manufacturer pay certain statutorilyprescribe rebate state medicaid programs prescription drug reimburse state medicaid plan effort state seek additional rebate affect abbvie business similarly veteran health care act prerequisite participation medicaid federal health care program require manufacturer extend additional discount pharmaceutical product federal agency include united states department veterans affairs department defense public health service entity institution addition recent legislative change require similarly discount price offer tricare program beneficiary veterans health care act establish b drug discount program require pharmaceutical manufacturer provide product reduce price designate health care entity facilities united states states generic substitution legislation require permit dispense pharmacist substitute different manufacturer generic version pharmaceutical product prescribe addition federal government follows diagnosisrelate group drg payment system certain institutional service provide medicare medicaid implement prospective payment system pps service deliver hospital outpatient nursing home home health setting drg pps entitle health care facility fix reimbursement base diagnosis andor procedure actual cost incur patient treatment increase incentive facility limit control expenditure health care product medicare reimburse b drug base average sale price plus certain percentage account physician administration cost recently reduce hospital outpatient set medicare enter contract private plan negotiate price patientadministere medicine deliver march congress enact patient protection affordable care act health care education reconciliation act affordable care act affordable care act abbvie pay fee relate pharmaceutical sale government program abbvie begin provide discount percent brand prescription drug sell patient fall medicare coverage gap donut hole affordable care act include provision know physician payment sunshine act require manufacturers drug biologics cover medicare medicaid start record transfer value physician teach hospital report datum beginning center medicare medicaid services subsequent public disclosure similar reporting requirement enact state level united states increase number country worldwide adopt consider similar law require disclosure interaction health care professional failure report appropriate datum result civil criminal fine andor penalty abbvie expect debate continue government level worldwide marketing availability method delivery payment health care product service abbvie believe future legislation regulation market serve affect access health care product service increase rebate reduce price rate price increase health care product service change health care delivery system create new fee obligation pharmaceutical industry require additional reporting disclosure possible predict extent abbvie health care industry general affect matter discuss abbvie subject corporate integrity agreement cia enter abbott require enhancement abbvie compliance program contain report obligation include disclosure financial payment doctor abbvie fail comply cia office inspector general united states department health human service impose monetary penalty exclude abbvie federal health care program include medicare medicaid european union european union adopt directive legislation govern label advertising distribution supply pharmacovigilance marketing pharmaceutical product legislation provide mandatory standard european union permit member states supplement standard additional regulation european government regulate pharmaceutical product price control national health care system fund large cost product consumer result patient unlikely use pharmaceutical product reimburse government european country government regulate price new product launch subsequent launch direct price control reference pricing recent year country impose new additional cost containment measure pharmaceutical product difference national pricing regime create price differential european union lead significant parallel trade pharmaceutical product government promote generic substitution mandate permit pharmacist substitute different manufacturer generic version pharmaceutical product prescribe permit mandate health care professional prescribe generic version certain circumstance addition government use reimbursement list limit pharmaceutical product eligible reimbursement national health care systems japan japan national health insurance system maintain drug price list specify pharmaceutical product eligible reimbursement ministry health labour welfare set price product list government generally introduce price cut round year mandate price decrease specific product new product judge innovative useful indicate pediatric use target orphan small population disease eligible pricing premium government promote use generic available emerge market emerge market step reduce pharmaceutical product price case direct price control promotion generic alternative brand pharmaceutical abbvie market product worldwide certain product local nature variation product line meet local regulatory requirement certain additional risk inherent conduct business outside united states include price currency exchange control change currency exchange rate limitation participation local enterprise expropriation nationalization governmental action employee abbvie employ approximately person january outside united states abbvie employee represent union work council abbvie believe good relation employee internet information copy abbvie annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act available free charge abbvie investor relation website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically file material furnish securities exchange commission sec abbvie corporate governance guideline outline directorship qualification code business conduct charters abbvie audit committee compensation committee nomination governance committee public policy committee available abbvie investor relation website wwwabbvieinvestorcom item risk factor carefully consider follow risk information evaluate abbvie abbvie common stock follow risk materially adversely affect abbvie result operation financial condition cash flow risk factor generally separate group risk relate abbvie business risk relate abbvie separation abbott risk relate abbvie common stock base information currently know abbvie believe follow information identify significant risk factor affect category risk risk uncertainty abbvie face limit set forth risk factor describe order importance probability occurrence additional risk uncertainty presently know abbvie abbvie currently believe immaterial adversely affect business addition past financial performance reliable indicator future performance historical trend anticipate result trend future period follow risk uncertainty develop actual event event material adverse effect abbvie business result operation financial condition cash flow case trading price abbvie common stock decline risk relate abbvie business expiration loss patent protection license adversely affect abbvie future revenue operate earning abbvie rely patent trademark intellectual property protection discovery development manufacturing sale product particular patent protection aggregate important abbvie marketing pharmaceutical product united states major market outside united states patent cover abbvie product normally provide market exclusivity important profitability abbvie product patent certain product expire abbvie face competition lower price generic product expiration loss patent protection product typically follow promptly substitute significantly reduce sale product short time abbvie competitive position compromise generic material adverse effect abbvie business result operation addition proposal emerge time time legislation encourage early rapid approval generic drug proposal enact law increase impact generic competition abbvie principal patent trademark describe great detail item businessintellectual property protection regulatory exclusivity item management discussion analysis financial condition result operationsresult operation litigation patent describe item legal proceeding united states composition matter patent humira abbvie large product worldwide net revenue approximately billion expect expire december equivalent european union patent expect expire majority european union country october humira biologic biologic readily substitute uncertain impact loss patent protection sale humira abbvie major product lose patent protection early expect adversely affect abbvie future revenue operate earning party government authority challenge seek invalidate circumvent abbvie patent patent application example manufacturer generic pharmaceutical product file continue file abbreviate new drug application fda seek market generic form abbvie product prior expiration relevant patent own license abbvie assert patent invalid unenforceable andor infringe addition petitioner file continue file challenge validity abbvie patent leahysmith america invents act create inter parte review post grant review procedure challenge patent validity administrative proceeding united states patent trademark office challenge abbvie intellectual property come business government challenge intellectual property right example court decision potential legislation relate patent legislation biosimilar regulatory initiative result erosion intellectual property protection addition certain government outside united states indicate compulsory license patent seek domestic policy basis national emergency hivaid trigger compulsory license diminish eliminate sale profit jurisdiction negatively affect abbvie result operation abbvie normally respond challenge vigorously defend patent include file patent infringement lawsuit patent litigation administrative proceeding challenge abbvie patent costly unpredictable deprive abbvie market exclusivity patent product extent abbvie intellectual property successfully challenge circumvent extent intellectual property allow abbvie compete effectively abbvie business suffer extent country enforce abbvie intellectual property right require compulsory licensing abbvie intellectual property abbvie future revenue operate earning reduce party intellectual property prevent abbvie selling product material adverse effect abbvie future profitability financial condition party claim abbvie product infringe intellectual property resolve intellectual property infringement claim costly time consuming require abbvie enter license agreement abbvie guarantee able obtain license agreement commercially reasonable term successful claim patent intellectual property infringement subject abbvie significant damage injunction prevent manufacture sale use affect abbvie product product event material adverse effect abbvie profitability financial condition significant event adversely affect humira revenue material negative impact abbvie result operation cash flow humira account approximately percent abbvie total net revenue significant event adversely affect humira revenue material adverse impact abbvie result operation cash flow event include loss patent protection humira approval biosimilar humira discovery previously unknown effect impair efficacy increase competition introduction new effective expensive treatment discontinuation removal market humira reason abbvie research development effort succeed develop marketing commercially successful product technology cause revenue profitability decline remain competitive abbvie continue launch new product new indication andor brand extension exist product launch generate revenue sufficient cover substantial research development cost replace revenue profitable product lose displace compete product therapy failure material adverse effect abbvie revenue profitability accordingly abbvie commit substantial effort fund resource research development ongoing substantial expenditure assurance effort commercially successful high rate failure biopharmaceutical industry inherent research development new product failure occur point research development process include significant fund invest product appear promise development fail reach market numerous reason include failure demonstrate effectiveness safety concern superior safety efficacy compete therapy failure achieve positive clinical preclinical outcome current standard care inability obtain necessary regulatory approval delay approval new product new indication limited scope approve use excessive cost manufacture failure obtain maintain intellectual property right infringement intellectual property right decision research study early development process pharmaceutical product candidate affect marketing strategy candidate receive approval detailed study demonstrate additional benefit help marketing consume time resource delay submit pharmaceutical product candidate approval abbvie guarantee proper balance speed testing respect pharmaceutical product candidate decision area adversely affect abbvie future result operation abbvie successfully develop market new product enhancement exist product quickly render obsolete change clinical preference change industry standard competitor innovation abbvie innovation accept quickly marketplace exist clinical practice uncertainty thirdparty reimbursement abbvie state certainty product development launch able develop license acquire compound product product commercially successful failure launch successful new product new indication exist product cause abbvie product obsolete cause abbvie revenue operate result suffer portion abbvie nearterm pharmaceutical pipeline rely collaboration party adversely affect development sale product abbvie depend alliance pharmaceutical biotechnology company portion product nearterm pharmaceutical pipeline example abbvie collaborate biogen develop treatment relapse remit form multiple sclerosis collaborate roche holding ag discover develop commercialize nextgeneration bcl inhibitor abt venetoclax patient relapsedrefractory chronic lymphocytic leukemia failure party meet contractual regulatory obligation abbvie disruption relationship abbvie party adverse effect abbvie pharmaceutical pipeline business addition abbvie collaborative relationship research development extend year rise dispute relative right obligation revenue abbvie collaboration partner include ownership intellectual property associate right obligation result loss intellectual property right protection delay development sale potential pharmaceutical product lead lengthy expensive litigation administrative proceeding arbitration biologic carry unique risk uncertainty negative impact future result operation successful discovery development manufacturing sale biologic long expensive uncertain process unique risk uncertainty biologic example access supply necessary biological material cell line limit governmental regulation restrict access regulate transport use material addition development manufacturing sale biologic subject regulation complex extensive regulation applicable pharmaceutical product manufacture biologic especially large quantity complex require use innovative technology manufacturing require facility specifically design validate purpose sophisticated quality assurance quality control procedure biologic frequently costly manufacture production input derive live animal plant material biologic synthetically failure successfully discover develop manufacture sell biologicsincluding humiracould adversely impact abbvie business result operation abbvie biologic product subject competition biosimilar biologics price competition innovation act pass march title vii patient protection affordable care act law create framework approval biosimilar united states allow competitor reference datum biologic product approve europe european commission grant marketing authorization biosimilar pursuant set general product classspecific guideline biosimilar approval issue past year addition company develop biosimilar country compete abbvie biologic product example amgen submit marketing authorization application european medicine agency biosimilar humira united states fda accept review amgen application humira biosimilar competitor able obtain marketing approval biosimilar reference abbvie biologic product abbvie product subject competition biosimilar attendant competitive pressure consequence expiration successful challenge abbvie applicable patent right trigger competition product assume relevant exclusivity period expire result abbvie face litigation administrative proceeding respect validity andor scope patent relate biologic product new product technological advance abbvie competitor negatively affect abbvie result operation abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete number antitnf product approve number disease state abbvie virology product compete protease inhibitor antihiv treatment competitor introduce new product develop technological advance compete abbvie product therapeutic area immunology virologyliver disease oncology dyslipidemia neuroscience abbvie predict certainty timing impact introduction competitor new product technological advance compete product safer effective effectively market sell low price superior performance feature abbvie product negatively impact abbvie business result operation manufacture abbvie product highly exact complex process abbvie supplier encounter problem manufacture abbvie product abbvie business suffer manufacture abbvie product highly exact complex process strict regulatory requirement problem arise manufacturing variety reason include equipment malfunction failure follow specific protocol procedure problem raw material delay relate construction new facility expansion exist facility include intended support future demand abbvie product change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation inhibit continuous supply manmade natural disaster environmental factor problem arise production batch product batch product discard abbvie experience product shortage incur add expense thing lead increase cost lose revenue damage customer relation time expense spend investigate cause depend cause similar loss respect batch product problem discover product release market recall product liability cost incur abbvie use number product pharmaceutical biologic manufacturing process source single supplier interruption supply product adversely affect abbvie business result operation abbvie use number product pharmaceutical biologic manufacturing process source single supplier failure singlesource supplier fulfill contractual obligation timely manner result regulatory noncompliance physical disruption manufacturing site impair abbvie ability deliver product customer timely competitive basis adversely affect abbvie business result operation find alternative supplier significant time involve significant expense nature product need obtain regulatory approval abbvie guarantee able reach agreement alternative provider regulatory authority approve abbvie use alternative abbvie carry business interruption insurance provide degree protection case failure singlesource supplier significant safety efficacy issue arise abbvie product material adverse effect abbvie revenue financial condition pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration follow regulatory approval product long period time patient investigator conduct additional extensive study new safety efficacy issue report new scientific information available include result postmarkete phase trial government change standard safety efficacy labeling abbvie require amend condition use product example abbvie voluntarily provide require provide update information product label narrow approve indication reduce product market acceptance safety efficacy issue abbvie product arise sale product halt abbvie regulatory authority safety efficacy issue affect supplier competitor product reduce market acceptance abbvie product new data abbvie product product similar product negatively impact demand abbvie product real perceive safety issue uncertainty efficacy case result product withdrawal furthermore new data information include information product misuse lead government agency professional society practice management group organization involve disease publish guideline recommendation relate use abbvie product use related therapy place restriction sale guideline recommendation lead low sale abbvie product abbvie subject product liability claim lawsuit adversely affect business result operation ordinary course business abbvie subject product liability claim lawsuit allege abbvie product product company promote result result unsafe condition injury patient product liability claim lawsuit safety alert product recall regardless ultimate outcome material adverse effect abbvie business result operation reputation ability attract retain customer consequence include additional cost decrease market share product question low income exposure claim product liability loss selfinsure abbvie subject costcontainment effort pricing pressure cause reduction future revenue operate earning change term rebate chargeback programs common pharmaceutical industry material adverse effect abbvie operation costcontainment effort government private organization describe great detail item businessregulation commercialization distribution manufacturing extent cost containment effort offset great demand increase patient access health care factor abbvie future revenue operate earning reduce united states european union country abbvie business experience downward pressure product pricing pressure increase future united states practice manage care group institutional governmental purchaser united states federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressure potential continue change health care system united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result additional pricing pressure numerous major market worldwide government play significant role fund health care service determine pricing reimbursement pharmaceutical product consequently market abbvie subject government decisionmake budgetary action respect product particular european country ongoing governmentmandate price reduction pharmaceutical product abbvie anticipate continue pricing pressure europe difference country pricing regulation lead thirdparty crossborder trading abbvie product result reduction future revenue operate earning rebate relate government program feeforservice medicaid medicaid manage care program arise law regulation abbvie predict additional government initiative contain health care cost factor lead new modify regulatory requirement include high incremental rebate discount rebate discount program arise contractual agreement private payer factor include market factor ability private payer control patient access product provide payer leverage negotiate high additional rebate discount material adverse effect abbvie operation abbvie subject numerous governmental regulation costly comply regulation develop compliant product process abbvie product subject rigorous regulation numerous international supranational federal state authority describe item businessregulationdiscovery clinical development process obtain regulatory approval market pharmaceutical product costly time consume approval grant future product additional indication use exist product timely basis delay receipt failure obtain approval future product new indication use result delay realization product revenue reduction revenue substantial additional cost addition abbvie guarantee remain compliant applicable regulatory requirement approval obtain product requirement include thing regulation manufacturing practice product label advertising post marketing reporting include adverse event report field alert manufacturing quality concern abbvie incur expense spend time effort ensure compliance complex regulation possible regulatory action result substantial modification abbvie business practice operation refund recall seizures abbvie product total partial shutdown production abbvie supplier facility abbvie supplier remedy allege violation inability obtain future approval withdrawal suspension current product market event disrupt abbvie business material adverse effect business result operation law regulation affect government benefit program impose new obligation abbvie require change business practice restrict operation future health care industry subject federal state international law regulation pertain government benefit program reimbursement rebate price reporting regulation health care fraud abuse united states law include antikickback false claim law medicaid rebate statute veterans health care act individual state law relate pricing sale marketing practice violation law punishable criminal andor civil sanction include instance substantial fine imprisonment exclusion participation federal state health care program include medicare medicaid veterans administration health program law regulation broad scope subject change evolving interpretation require abbvie incur substantial cost associate compliance alter sale marketing practice addition violation law allegation violation disrupt abbvie business result material adverse effect business result operation abbvie subject increase monetary penalty andor sanction include exclusion federal health care program fail comply term resolution department justice investigation sale marketing activity depakote abbott settle united states federal state investigation sale marketing activity depakote plead guilty misdemeanor violation food drug cosmetic act agree pay approximately million criminal fine forfeiture approximately million resolve civil claim submit term probation term probation end january abbvie satisfy probation condition abbvie violate remain term plea agreement face additional monetary sanction remedy court deem appropriate addition abbott enter fiveyear cia office inspector general united states department health human service oig effective date cia october obligation cia transfer fully bind abbvie cia require enhancement abbvie compliance program fulfillment report monitoring obligation management certification resolution abbvie board director requirement compliance requirement settlement impose additional cost burden abbvie include form employee training party review compliance monitoring report obligation management attention abbvie fail comply cia oig impose monetary penalty exclude abbvie federal health care program include medicare medicaid abbvie abbott subject party claim shareholder lawsuit connection settlement abbvie require indemnify portion abbott cost international nature abbvie business subject additional business risk cause revenue profitability decline abbvie business subject risk associate business internationally include emerge market net revenue outside united states approximately percent abbvie total net revenue risk associate abbvie operation outside united state include fluctuation currency exchange rate change medical reimbursement policy program multiple legal regulatory requirement subject change restrict abbvie ability manufacture market sell product differ local product preference product requirement trade protection measure import export licensing requirement difficulty establish staffing manage operation differ labor regulation potentially negative consequence change interpretation tax law political economic instability include sovereign debt issue price currency exchange control limitation participation local enterprise expropriation nationalization governmental action inflation recession fluctuation interest rate potential deterioration economic position credit quality certain nonus country include europe latin america potential penalty adverse consequence violation anticorruption antibribery similar law regulation include united states foreign corrupt practice act united kingdom bribery act event contemplate risk individually aggregate material adverse effect abbvie revenue profitability abbvie ability realize anticipate benefit merger pharmacyclic depend ability effectively profitably commercialize imbruvica ibrutinib anticipate benefit abbvie merger pharmacyclic depend abbvie ability effectively profitably commercialize imbruvica include abbvie ability create meet continue market demand achieve market acceptance generate product sale ensure active pharmaceutical ingredient imbruvica finish product manufacture sufficient quantity compliance requirement fda similar foreign regulatory agency acceptable quality pricing meet commercial demand ensure entire supply chain efficiently consistently deliver imbruvica abbvie customer commercialization imbruvica successful thing unexpected challenge competitor new safety issue concern report impact narrow approve indication relative price imbruvica compare alternative treatment option change label imbruvica restrict marketing commercialization imbruvica unsuccessful abbvie ability generate revenue product sale realize anticipated benefit merger adversely affect abbvie acquire business license right technology product form alliance dispose asset cause incur significant expense negatively affect profitability abbvie pursue acquisition technology licensing arrangement strategic alliance dispose asset business strategy abbvie complete transaction timely manner costeffective basis realize expect benefit abbvie successful making acquisition product technology acquire successful require significantly great resource investment originally anticipate abbvie able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability abbvie experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment long term asset effect cause deterioration abbvie credit rating result increase borrowing cost interest expense additionally change abbvie structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate abbvie dependent wholesale distributor distribution product united states accordingly result operation adversely affect encounter financial difficulty wholesale distributorsamerisourcebergen corporation cardinal health inc mckesson corporationaccounte substantially abbvie net revenues united states significant wholesale distributor encounter financial difficulty distributor decrease business abbvie abbvie unable collect amount distributor owe timely basis negatively impact abbvie business result operation abbvie debt obligation adversely affect business ability meet obligation debt abbvie incur intend incur important consequence abbvie investor consequence include thing require portion abbvie cash flow operation interest payment debt reduce cash flow available fund capital expenditure corporate purpose grow abbvie business extent abbvie incur additional indebtedness risk increase addition abbvie cash flow operation sufficient repay outstanding debt abbvie able borrow money sell asset raise fund acceptable term refinance debt abbvie need additional financing future meet capital need opportunistic acquisition financing available favorable term abbvie need seek additional financing general corporate purpose example need increase investment research development activity need fund acquisition abbvie unable obtain desire additional financing term favorable abbvie lose investment grade credit rating adequate fund available acceptable term abbvie unable fund expansion successfully develop enhance product respond competitive pressure negatively affect abbvie business abbvie raise additional fund issue debt enter credit facility subject limitation operation restrictive covenant failure comply covenant adversely affect abbvie business abbvie depend information technology failure system adversely affect abbvie business abbvie rely sophisticated information technology system operate business system potentially vulnerable malicious intrusion random attack loss datum privacy breakdown abbvie invest protection datum information technology monitor system ongoing basis assurance effort prevent breakdown breaches abbvie information technology system adversely affect abbvie business factor material adverse effect abbvie profitability financial condition factor affect abbvie result operation cash flow financial condition include change interpretation law regulation include change accounting standard taxation requirement product marketing application standard environmental law difference fair value measurement asset liability actual value particularly pension post employment benefit stockbase compensation intangible goodwill contingent liability litigation absence record record minimum compare actual change rate inflation include cost raw material commodity supply interest rate market value abbvie equity investment performance investment hold employee benefit trust change creditworthiness counterpartie transact business provide service abbvie employee benefit trust change ability party provide information technology account human resource payroll outsource service abbvie meet contractual obligation abbvie change business economic political condition include war political instability terrorist attack threat future terrorist activity relate military action natural disaster cost availability insurance forego event labor dispute strike slowdown form labor union activity pressure thirdparty interest group risk relate abbvie common stock abbvie guarantee timing payment dividend common stock abbvie expect pay regular cash dividend time declaration payment future dividend stockholder fall discretion abbvie board director board decision payment dividend depend factor abbvie financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant information item market registrant common equity relate stockholder matter issuer purchase equity security abbvie ability pay dividend depend ongoing ability generate cash operation access capital market abbvie guarantee continue pay dividend future abbvie stockholder percentage ownership abbvie dilute future future stockholder percentage ownership abbvie dilute equity issuance capital market transaction equity awards abbvie grant abbvie director officer employee acquisition purpose abbvie employee option purchase share common stock result conversion abbott stock option abbvie stock option abbvie anticipate compensation committee grant additional stock option stockbase award employee award dilutive effect abbvie earning share adversely affect market price abbvie common stock time time abbvie issue additional option stockbase award employee abbvie employee benefit plan addition abbvie amend restate certificate incorporation authorize abbvie issue approval abbvie stockholder class series prefer stock designation power preference relative participate optional special right include preference abbvie common stock respect dividend distribution abbvie board director generally determine term class series prefer stock dilute voting power reduce value abbvie common stock example abbvie grant holder prefer stock right elect number abbvie director event happen specify event right veto specify transaction similarly repurchase redemption right liquidation preference abbvie assign holder prefer stock affect residual value common stock certain provision abbvie amend restate certificate incorporation amend restate bylaw delaware law prevent delay acquisition abbvie decrease trading price abbvie common stock abbvie amend restate certificate incorporation amend restate bylaw contain delaware law contain provision intend deter coercive takeover practice inadequate takeover bid make practice bid unacceptably expensive bidder encourage prospective acquiror negotiate abbvie board director attempt hostile takeover provision include inability abbvie stockholder special meeting division abbvie board director class director class serve stagger threeyear term provision stockholder remove director cause ability abbvie director stockholder fill vacancy abbvie board director requirement affirmative vote stockholder hold percent abbvie voting stock require amend certain provision abbvie amend restate certificate incorporation abbvie amend restate bylaw relate number term election abbvie director fill board vacancy call special meeting stockholder director officer indemnification provision addition section delaware general corporation law provide subject limited exception person acquire affiliated person acquire percent outstanding voting stock delaware corporation shall engage business combination corporation include merger consolidation acquisition additional share threeyear period follow date person affiliate holder percent corporation outstanding voting stock abbvie believe provision protect stockholder coercive unfair takeover tactic require potential acquiror negotiate abbvie board director provide abbvie board director time assess acquisition proposal provision intend company immune takeover provision apply offer consider beneficial stockholder delay prevent acquisition abbvie board director determine good interest abbvie abbvie stockholder provision prevent discourage attempt remove replace incumbent director cautionary statement forwardlooke statement annual report contain certain forward look statement business strategy market potential future financial performance matter word believe expect anticipate project similar expression generally identify forward look statement speak date statement matter discuss forward look statement subject risk uncertainty factor cause actual result differ materially project anticipated imply forward look statement particular information include item business item risk factor item management discussion analysis financial condition result operation contain forward look statement forward look statement expectation belief future result event express expectation belief base current plan expectation abbvie management express good faith believe reasonable basis assurance expectation belief result achieve accomplished factor cause actual result event differ materially anticipate include matter describe item risk factor item management discussion analysis financial condition result operation abbvie undertake obligation update forwardlooke statement include annual report reflect event circumstance date hereof abbvie require applicable security law item b unresolved staff comment item property abbvie corporate office locate north waukegan road north chicago illinois abbvie principal manufacturing plant follow location united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois sligo ireland worcester massachusetts lease property addition abbvie manufacturing facility united states worldwide abbvie believe facility suitable provide adequate production capacity united states include puerto rico abbvie distribution center abbvie research development facilities united states locate abbott park illinois north chicago illinois redwood city california worcester massachusetts outside united states abbvie principal research development facility locate ludwigshafen germany note principal plant united states list own abbvie subsidiary abbvie remain manufacturing plant facility own lease abbvie subsidiary abbvie item legal proceeding information pertain legal proceeding provide note entitle legal proceeding contingency note consolidated financial statement include item financial statement supplementary datum incorporate reference item safety disclosure applicable executive officer registrant follow table list abbvie executive officer appoint abbvie corporate officer december indicate age position richard gonzalez chairman board chief executive officer carlos alban executive vice president commercial operation william j chase executive vice president chief financial officer henry gosebruch executive vice president chief strategy officer laura j schumacher executive vice president external affairs general counsel corporate secretary michael e severino md executive vice president research development chief scientific officer timothy j richmond senior vice president human resource azita salekigerhardt phd senior vice president operation thomas hurwich vice president controller appoint corporate officer december appoint corporate officer june mr gonzalez abbvie chairman board chief executive officer serve abbott executive vice president pharmaceutical product group responsible abbott worldwide pharmaceutical business include commercial operation research development manufacturing serve president abbott ventures inc abbott medical technology investment arm mr gonzalez join abbott hold management position briefly retire include abbott president chief operating officer president chief operating officer abbott medical product group senior vice president president abbott hospital product division hospira inc vice president president abbott health system division divisional vice president general manager abbott diagnostic operation united states canada mr alban abbvie executive vice president commercial operation serve abbott senior vice president proprietary pharmaceutical product global commercial operation senior vice president international pharmaceutical vice president western europe canada vice president european operations mr alban join abbott mr chase abbvie executive vice president chief financial officer serve abbott vice president license acquisition vice president treasurer divisional vice president controller abbott international mr chase join abbott mr gosebruch abbvie executive vice president chief strategy officer work year merger acquisition group jp morgan securities llc serve manage director cohead north america mr gosebruch join abbvie ms schumacher abbvie executive vice president external affairs general counsel corporate secretary responsible abbvie externallyface function health economic outcome research government affair corporate responsibility brand communication lead legal function biotherapeutic strategy prior abbvie separation abbott ms schumacher serve executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel abbott abbvie ms schumacher lead licensing acquisition venture early stage collaboration abbott ms schumacher responsible office ethic compliance ms schumacher join abbott serve board general dynamic corporation dr severino abbvie executive vice president research development chief scientific officer dr severino serve amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development join abbvie mr richmond abbvie senior vice president human resource serve abbott divisional vice president compensation benefit group vice president talent reward divisional vice president talent acquisition mr richmond join abbott dr salekigerhardt abbvie senior vice president operation serve abbott vice president pharmaceutical manufacturing supply divisional vice president quality assurance global pharmaceutical operation dr saleki gerhardt join abbott mr hurwich abbvie vice president controller serve abbott vice president internal audit divisional vice president controller abbott diagnostics division mr hurwich join abbott executive officers abbvie elect annually board director officer elect board appoint chairman board officer elect meeting board director hold annual stockholder meeting appoint chairman board board meeting officer hold office successor duly elect appoint qualified officer death resignation removal family relationship executive officer list ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market principal market abbvie common stock new york stock exchange nyse abbvie common stock list chicago stock exchange trade regional electronic exchange outside united states abbvie common stock list nyse euronext paris swiss exchange market price share high low high low quarter second quarter quarter fourth quarter stockholder stockholder record abbvie common stock january dividend quarterly dividend pay common stock quarter cash dividend share payable february second fourth quarter dividend share payable august november respectively quarter cash dividend share payable february second fourth quarter dividend share payable august november respectively october abbvie board director declare increase quarterly cash dividend share share payable february stockholders record january time declaration payment dividend abbvie future discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director abbvie determine pay dividend future assurance continue pay dividend dividend performance graph follow graph compare cumulative total return abbvie sp index nyse arca pharmaceuticals index graph cover period january day abbvie common stock begin regularway trading nyse december graph assume invest abbvie common stock index january assume reinvestment dividend stock price performance follow graph necessarily indicative future stock price performance comparison cumulative total return performance graph furnish shall deem file sec subject section security exchange act shall deem incorporate reference filing securities act amend issuer purchase equity security c total number maximum number share b unit approximate dollar average purchase value total price share unit number pay publicly share announce purchase unit share plan period purchase unit program plan programs october october november november december december total addition abbvie share repurchase open market publicly announce program share include follow share deem surrender abbvie pay exercise price connection exercise employee stock option october november december ii share purchase open market benefit participant abbvie employee stock purchase plan october november december share include share surrender abbvie satisfy minimum tax withholding obligation connection vest restricted stock restrict stock unit october abbvie announce board director authorize purchase billion common stock purchase abbvie share program time time management discretion program time limit discontinue time item select financial datum follow table set forth abbvie select financial information derive audit consolidated financial statement year end december ii audit combine financial statement year end december historical financial statement period prior january prepare standalone basis derive abbott consolidated financial statement accounting record researchbase pharmaceutical business abbott abbvie period present accordingly abbvie financial statement period prior january present combined basis reflect abbvie financial position result operation cash flow business operate abbott prior separation conformity generally accept accounting principle gaap united states select financial information read conjunction financial statement accompany note include item financial statement supplementary datum item management discussion analysis financial condition result operation year end december millions share datum statement earning datum net revenue net earningsab basic earning shareab dilute earning shareab cash dividend declare share c na na weightedaverage basic share outstandingd weightedaverage diluted share outstandingd balance sheet datum total assetse longterm debt lease obligationsef nanot applicable abbvie historical financial statement period prior january reflect allocation expense relate certain abbott corporate function include senior management legal human resource finance information technology quality assurance expense allocate abbvie base direct usage benefit identifiable remainder allocate pro rata basis revenue headcount square footage number transaction measure abbvie consider expense allocation methodology result reasonable allocation indicative actual expense incur abbvie operate independent standalone publiclytrade company period present accordingly historical financial information present period prior january indicative result operation financial position achieve abbvie independent standalone publiclytrade company period show abbvie performance period subsequent december b result include high expense associate operate independent standalone publicly trade company historically derive financial statement period prior january increase include impact interest expense debt issue november high tax rate incremental cost operate independent company refer management discussion analysis financial condition result operation result operation discussion item affect comparability financial result c abbvie declare regular quarterly cash dividend aggregate share common stock addition cash dividend share common stock declare preseparation earning january record reduction additional paidin capital january abbott distribute million share abbvie common stock shareholder abbott common stock period prior separation weightedaverage basic dilute share outstanding base number share abbvie common stock outstanding distribution date refer note audit consolidated financial statement include item financial statement supplementary data information calculation basic diluted earning common share e abbvie acquire pharmacyclic inc approximately billion include cash consideration billion equity consideration approximately million share abbvie common stock value billion connection acquisition abbvie issue billion aggregate principal unsecured senior note approximately billion finance acquisition pharmacyclics inc approximately billion finance accelerate share repurchase agreement refer note audit consolidated financial statement include item financial statement supplementary data information acquisition pharmacyclic inc senior note accelerate share repurchase program respectively f include current portion longterm debt lease obligation item management discussion analysis financial condition result operation follow discussion analysis financial condition abbvie inc abbvie company december result operation year period end december commentary read conjunction consolidated financial statement accompany note appear item financial statement supplementary data executive overview company overview abbvie global researchbase biopharmaceutical company form follow separation abbott laboratories abbott abbvie mission use expertise dedicated people unique approach innovation develop market advanced therapy address world complex disease abbvie product focus treat condition chronic autoimmune disease rheumatology gastroenterology dermatology oncology include blood cancer virology include hepatitis c hcv human immunodeficiency virus hiv neurological disorder parkinson disease metabolic disease include thyroid disease complication associate cystic fibrosis health condition abbvie pipeline promise new medicine important medical specialty immunology virologyliver disease oncology neurology cystic fibrosis woman health abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie patient outside united states sale directly customer distributor depend market serve certain product comarkete co promote company abbvie approximately employee abbvie operate business segmentpharmaceutical product abbvie complete acquisition pharmacyclic inc pharmacyclic biopharmaceutical company develop commercialize novel therapy people impact cancer flagship asset imbruvica ibrutinib novel orally active selective covalent inhibitor bruton tyrosine kinase btk worldwide collaboration license agreement janssen biotech inc janssen pharmaceutical companies johnson johnson janssen imbruvica approve use united states canada european union eu country worldwide united states abbvie comarkets imbruvica indication approve food drug administration fda prior acquisition date treatment patient mantle cell lymphoma mcl receive prior therapy ii treatment patient chronic lymphocytic leukemia cll receive prior therapy iii treatment cll patient deletion short arm chromosome del p cll iv treatment patient waldenstrom macroglobulinemia eu janssen markets imbruvica date acquisition imbruvica indicate eu treatment adult patient relapse refractory mcl adult patient cll receive prior therapy firstline presence p deletion tp mutation patient unsuitable chemoimmunotherapy acquisition accelerate abbvie clinical commercial presence oncology strengthen pipeline establish leadership position hematological oncology acquisition accelerate abbvie revenue earning growth diversify revenue base abbvie expect acquisition accretive earning beginning refer note entitle licensing acquisition arrangement note condense consolidated financial statement include ii item financial statement supplementary data information acquisition pharmacyclic financial result abbvie strategy focus deliver strong financial result advance invest pipeline return value shareholder ensure strong sustainable growth business long term abbvie worldwide net revenue grow percent billion drive primarily continue strength humira united states internationally global launch abbvie interferonfree hcv treatment revenue growth key product include creon duodopa postacquisition revenue relate imbruvica increase partially offset decline net revenue androgel principally continued market decline entry generic competition androgel formulation continue decline company lipid franchise unfavorable impact foreign exchange company financial performance include deliver fully dilute earning share include aftertax cost total million incur connection acquisition integration pharmacyclic million aftertax charge purchase rare pediatric disease priority review voucher prv united therapeutics corporation million aftertax charge result enter exclusive worldwide license agreement cn diagnostic cn aftertax foreign exchange loss million result liquidation remain foreign currency position relate terminate propose combination shire plc shire aftertax charge million increase company litigation reserve million aftertax charge achievement development milestone global collaboration infinity pharmaceuticals inc infinity refer note information item abbvie financial performance reflect improvement gross margin percent net revenue primarily favorable product mix product portfolio operating efficiency impact foreign exchange rate financial result reflect continue funding support abbvie emerge midand latestage pipeline asset continue investment abbvie growth brand global launch abbvie interferonfree hcv treatment viekira pak company generate cash flow operation billion cash flow enable company pay cash dividend shareholder billion repurchase approximately million share billion open market exclude share repurchase accelerate repurchase agreement continue enhance pipeline licensing collaboration activity include million payment calico life sciences llc calico result satisfaction certain condition research development rd collaboration calico charge acquire inprocess research development iprd record addition abbvie issue billion aggregate principal senior note proceed finance acquisition pharmacyclic billion accelerated share repurchase agreement asr pursuant abbvie pay billion aggregate million share abbvie common stock october abbvie board director declare quarterly cash dividend share common stock payable february reflect increase approximately percent previous quarterly rate share common stock strategic objective abbvie mission innovationdriven patientfocuse specialty biopharmaceutical company capable achieve topti financial performance outstanding execution consistent stream innovative new medicine abbvie intend continue advance mission number way include grow revenue continue strong performance exist portfolio onmarket product include flagship brand humira imbruvica viekira pak growth pipeline product ii expand gross operating margin iii continued investment pipeline support opportunitie immunology oncology virology continue investment key onmarket product iv augmentation pipeline concert focus strategic licensing acquisition partner activity focus identify compelling program fit abbvie strategic criterion v return cash shareholder dividend share repurchase addition abbvie anticipate regulatory submission key data readout key clinical trial abbvie expect achieve revenue growth objective follow humira sale growth drive biologic penetration disease category increase market leadership strong commercial execution expansion new indication hidradenitis suppurativa regulatory approval united states eu achieve uveitis regulatory submission united states eu review approval expect imbruvica revenue growth drive increase market share currently approve indication indication expansion imbruvica firstline therapy cll currently priority review fda revenue benefit year imbruvica revenue viekira pak revenue growth drive continue uptake geography include japan second large hcv market globally indication expansion oncedaily fixeddose formulation viekira pak treat genotype gt hcv currently review favorable impact pipeline product approve currently regulatory review approval expect include venetoclax empliciti elotuzumab zinbryta daclizumab pipeline product describe great detail section label research development include item abbvie remain committed drive continued expansion gross operating margin expect achieve objective productivity initiative supply chain ongoing efficiency program optimize manufacture commercial infrastructure administrative cost general corporate expense continue leverage revenue growth abbvie remain committed return cash shareholder dividend share repurchase research development research innovation cornerstone abbvie business global biopharmaceutical company abbvie longterm success depend great extent ability continue discover develop innovative pharmaceutical product acquire collaborate compound currently development biotechnology pharmaceutical company abbvie pipeline currently include compound indication clinical development individually collaboration license agreement focus important medical specialty immunology oncology virologyliver disease neurology target investment renal disease cystic fibrosis woman health program mid latestage development follow section summarize transition significant program phase development phase development development significant phase registration program abbvie expect multiple phase program transition phase program significant clinical program approve submit abbvie submit review receive approval follow significant latestage development program immunology fda grant humira orphan drug designation treatment moderatetosevere hidradenitis suppurativa hs painful chronic inflammatory skin disease abbvie supplemental biological license application bla united states marketing authorization eu approve fda european medicine agency ema respectively approval indication represent thirteenth indication humira major geography world april abbvie announce european commission ec grant marketing authorization humira treatment severe chronic plaque psoriasis child adolescence year age inadequate response inappropriate candidate topical therapy phototherapy ec decision humira approve use indication member states eu abbvie submit regulatory application united states eu use humira treatment uveitis abbvie expect receive regulatory approval oncology july abbvie announce ec grant marketing authorization imbruvica treatment option specifically approve treatment adult patient waldenstrom macroglobulinemia rare slow grow blood cancer pharmacyclic receive fda approval imbruvica patient waldenstrom macroglobulinemia january ec approval trigger million milestone payment janssen september abbvie announce submit supplemental new drug application snda fda imbruvica treatmentnave cll patient snda base result phase resonate study evaluate efficacy safety imbruvica versus traditional chemotherapy chlorambucil treatmentnave cll patient age year old application receive priority review november abbvie submit snda fda label consideration base safety efficacy result phase helios trial investigate use imbruvica bendamustine rituximab versus placebo plus bendamustine rituximab patient relapsedrefractory cll small lymphocytic lymphoma february fda grant imbruvica orphan drug designation treatment patient extranodal marginal zone lymphoma abbvie submit regulatory application united states eu venetoclax abt inhibitor bcell lymphoma bcl protein develop collaboration genentech roche holding ag priority review status grant fda validation provide ema submission venetoclax phase development patient relapsedrefractory cll addition venetoclax grant breakthrough therapy designation fda treatment cll previously treat relapsedrefractory patient p deletion mutation ii combination rituximab treatment patient relapsedrefractory cll include patient chromosome p deletion iii combination hypomethylate agent treatment patient untreate treatmentnave acute myeloid leukemia ineligible receive standard induction therapy highdose chemotherapy registration submission submit fda ec empliciti elotuzumab signal lymphocyte activation molecule slamdirecte immunostimulatory antibody develop partnership bristolmyer squibb bms firstline relapsedrefractory multiple myeloma mm subsequently ema validate review marketing authorization application empliciti elotuzumab treatment mm combination therapy adult patient receive prior therapy application grant accelerated assessment ema committee medicinal product human use chmp addition fda approve empliciti elotuzumab treatment mm combination therapy patient receive prior therapy fda approval immunestimulatory antibody mm indication empliciti market bms virologyliver disease january abbvie announce ec grant marketing authorization alloral shortcourse interferonfree treatment viekirax ombitasvirparitaprevirritonavir tablet exviera dasabuvir tablet treatment approve ribavirin rbv patient gt chronic hcv infection include compensate liver cirrhosis hiv coinfection patient opioid substitution therapy liver transplant recipient additionally viekiraxexviera approve use rbv genotype gt chronic hcv patient abbvie regulatory application japan company alloral rbv interferonfree week directacting antiviral treatment ombitasvirparitaprevirritonavir obvptvr dose daily approve september treatment patient gt chronic hcv infection july fda approve abbvie regulatory application technivie obvptvr tablet combination rbv treatment adult gt chronic hcv infection cirrhosis technivie alloral interferonfree directacting antiviral treatment approve united states adult patient gt chronic hcv infection abbvie submit regulatory application united states oncedaily fixeddose formulation viekira pak treat gt hcv propose dose fixeddose formulation oral tablet take daily meal rbv abbvie anticipate regulatory action new formulation fda accept abbvie snda grant priority review viekira pak rbv patient genotype b gtb chronic hcv infection compensate cirrhosis childpugh neurology january abbvie announce fda approve duopa carbidopa levodopa enteral suspension treatment motor fluctuation people advanced parkinson disease duopa administer small portable infusion pump deliver carbidopa levodopa directly small intestine continuous hour procedurallyplaced tube product sell duodopa outside united states abbvie collaborate biogen develop zinbryta daclizumab anticd monoclonal antibody treatment relapsingremitte form multiple sclerosis ms february registration submission zinbryta united states follow eu submission march march abbvie biogen announce ema validate company marketing authorization application zinbryta treatment relapse form ms eu validation confirm submission complete signify initiation review process chmp april abbvie biogen announce fda accept review registration submission united states significant development transition significant program phase phase development significant development include follow immunology january abbvie announce commencement phase clinical trial program study use abbvie oncedaily formulation abt internally develop investigational selective janus kinase jak inhibitor treatment rheumatoid arthritis phase trial abt treatment crohn disease ongoing abbvie receive decision ec compliance pediatric investigation plan humira ensure necessary datum obtain study child result positive decision company seek extension eu member state supplementary protection certificate hold approve extend humira composition matter patent eu month april october oncology july abbvie initiate phase study use veliparib abt parpinhibitor treatment ovarian cancer combination chemotherapy veliparib phase development form breast lung cancer abbvie recently initiate phase clinical trial imbruvica solid tumor trial evaluate safety efficacy imbruvica combination gemcitabine nabpaclitaxel firstline treatment patient metastatic pancreatic adenocarcinoma virologyliver disease october consultation fda product inserts united states viekira pak technivie update recommend childpugh b patient contraindication patient childpugh b cirrhosis patient classify childpugh c remain contraindicated approval january abbvie initiate phase clinical trial program evaluate safety efficacy nextgeneration alloral daily pangenotypic rbvfree investigational hcv regiman include abt nsa protease inhibitor abt nsa inhibitor abbvie develop novel oral gonadotropinrelease hormone gnrh antagonist elagolix collaboration neurocrine bioscience neurocrine treatment endometriosisrelate pain uterine fibroid january abbvie announce initiation plan phase study evaluate safety efficacy elagolix treatment patient uterine fibroid abbvie milestone payment million neurocrine enrollment patient elagolix latestage development endometriosis abbvie enter collaboration galapagos nv galapagos develop filgotinib oral jak inhibitor follow thorough review available datum abbvie announce exercise right inlicense filgotinib galapago pursuant term global collaboration agreement galapago right filgotinib revert solely galapagos abbvie augment pipeline strategic licensing partnering activity include inlicense antitau antibody abbv e treatment alzheimer disease neurological disorder cn privately hold protein diagnostic therapeutic discovery company refer note note consolidated financial statement include item financial statement supplementary data information license agreement cn result operation net revenue comparison present constant currency rate reflect comparative local currency net revenue prior year foreign exchange rate measure provide information change net revenue assume foreign currency exchange rate change prior current period abbvie believe nongaap measure change net revenue constant currency rate conjunction gaap measure change net revenue actual currency rate provide complete understand company operation facilitate analysis company result operation particularly evaluate performance period percent change actual constant currency currency rate rate year end millions united states international net revenue follow table detail abbvie worldwide net revenue percent change actual constant currency currency rate rate year end december millions humira united states international total imbruvica united states na na na na collaboration revenue na na na na total na na na na viekira united states nm nm international na na na na total nm nm creon united states synagi international lupron united states international total synthroid united states kaletra united states international total androgel united states sevoflurane united states international total duodopa united states nm na nm na international total dyslipidemia product united states total net revenue nmnot meaningful nanot applicable follow discussion analysis abbvie net revenue product present constant currency basis global humira sale increase percent primarily result market growth therapeutic category geographie high market share approval new indication favorable pricing certain geography united states humira revenues increase percent percent drive prescription volume favorable pricing market growth indication internationally humira revenue increase percent percent drive primarily growth indication certain geography abbvie continue pursue new indication help differentiate humira compete product add sustainability future growth humira net revenues imbruvica represent product revenues united states collaboration revenue relate abbvie percent share imbruvica profit outside united states follow completion acquisition pharmacyclic abbvie expect imbruvica significant contributor revenue growth abbvie launch hcv regiman viekira pak united states follow fda approval middecember launch viekiraxexviera eu january addition growth approve market international revenue continue increase product approve additional geography net revenues viekira pak reflect shipment launch quantity market support commercial launch net revenue creon increase percent percent drive primarily continue market growth high market share creon maintain market leadership pancreatic enzyme market synagis seasonal product majority sale occur fourth quarter net revenue increase percent percent revenue reflect change demand certain market unfavorable comparison drive severe respiratory syncytial virus season global lupron net revenue increase percent primarily increase demand favorable pricing united states lupron continue hold leadership position maintain significant share market global kaletra net revenue decline percent percent primarily low market share result impact increase competition hiv marketplace androgel net revenue decline percent percent primarily continue decline overall testosterone replacement market entry generic competition androgel formulation january company expect testosterone replacement market continue decline net revenue duodopa abbvie therapy advanced parkinson disease approve europe international market grow percent abbvie regulatory submission duopa united states approve fda january abbvie expect net revenue duopa united states continue gradually increase product gain acceptance marketplace net revenue abbvie consolidated lipid franchise include tricor trilipix niaspan simcor advicor decline percent percent introduction generic version product market generic competition begin november tricor july trilipix september niaspan abbvie voluntarily withdraw simcor advicor market discontinue distribution december net revenue decline percent primarily reduce demand drive market share decline reduction price abbvie mature onmarket product gross margin percent change year end december millions gross margin percent net revenue gross margin reflect favorable impact product mix product portfolio include humira operational efficiency price increase partially offset effect unfavorable foreign exchange rate loss exclusivity lipid franchise gross margin include milestone revenue million collaboration partner relate company oncology program gross margin include royalty income million relate prior period result settlement licensing arrangement low amortization expense intangible asset partially offset million impairment charge intangible asset sell general administrative percent change year end december million sell general administrative percent net revenue sell general administrative sga expense decline compare principally absence transactionrelate cost total billion incur connection termination propose combination shire discuss note note consolidated financial statement sga expense include million charge relate brand prescription drug fee issuance final rule result additional year expense refer note information exclude item sga expense increase reflect increase selling marketing support new product include global launch viekira spending relate new indication geographic expansion humira growth brand sga expense include pharmacyclic acquisition integration cost million charge aggregate million increase company litigation reserve restructure charge million increase cost partially offset impact favorable foreign exchange rate research development acquire inprocess research development percent change year end december million research development percent net revenue acquire inprocess research development rd expense include pharmacyclic acquisition integration cost million million charge relate purchase priority review voucher party million charge record achievement development milestone collaboration infinity postacquisition rd expense pharmacyclic restructuring charge million rd expense include regulatory milestone payment million collaboration partner regulatory milestone relate company hcv program restructuring charge million respectively rd expense reflect add funding support company emerge mid latestage pipeline asset continue pursuit additional humira indication increase partially offset impact favorable foreign exchange rate iprd expense include charge million result enter exclusive worldwide license agreement cn develop commercialize antitau antibodie treatment alzheimer disease neurological disorder iprd expense include charge million result enter global collaboration infinity develop commercialize duvelisib treatment patient cancer iprd expense include charge million result enter global license agreement ablynx nv develop commercialize alx charge million result enter global collaboration alvine pharmaceuticals inc develop alv charge million result enter global collaboration galapago cystic fibrosis therapie charge total million result enter arrangement refer note note consolidated financial statement additional information relate company collaboration arrangement operating expense operating expense include million charge relate rd collaboration agreement enter september calico discover develop commercialize new therapy patient agerelate disease nonoperate expense interest expense net million million million comprise primarily interest expense outstanding debt interest expense net increase issuance billion aggregate principal senior note issue primarily finance acquisition pharmacyclic accelerate share repurchase program interest expense net include million bridge financing relate fee incur connection acquisition pharmacyclic interest expense net include million financing relate fee incur connection terminate propose combination shire abbvie enter certain undesignated forward contract hedge anticipate foreign currency cash outflow associate propose combination shire net foreign exchange loss include loss million associate shirerelate forward contract net foreign exchange loss include loss total million reflect complete liquidation company remain foreign currency position relate terminate propose combination shire nonoperate expense net include impairment charge total million relate certain company equity investment security nonoperate income net primarily consist income million resolution contractual agreement income tax expense effective income tax rate percent percent percent effective tax rate fluctuate year year allocation company taxable earning jurisdiction certain discrete factor event year include acquisition collaboration effective income tax rate include tax benefit million reduction state valuation allowance effective income tax rate include state valuation allowance million additional expense million relate brand prescription drug fee nondeductible financial position liquidity capital resource year end december million cash flow provide byused operating activity invest activity financing activity cash flow provide operation billion compare billion increase primarily improved result operation revenue growth improvement operating margin absence aftertax transaction financingrelate cost billion incur connection termination propose combination shire include net foreign exchange loss relate settlement undesignate forward contract hedge anticipate foreign currency cash flow exit certain foreign currency position cash provide operating activity reflect abbvie voluntary contribution main domestic define benefit plan million million respectively abbvie voluntary contribution million plan subsequent december abbvie pay million purchase priority review voucher united therapeutics corporation realize excess tax benefit associate stockbase compensation total million million million respectively present consolidated statement cash flow outflow operating section inflow financing section investing activity primarily include billion cash consideration pay acquire pharmacyclic net cash acquire million investing activity include cash outflow related acquisition investment million include million payment calico accrue satisfaction certain condition rd collaboration million relate exclusive worldwide license agreement cn develop commercialize antitau antibodie treatment alzheimer disease neurological disorder million pay infinity achievement development milestone collaboration agreement cash outflow related acquisition investment total million include million pay infinity relate global collaboration develop duvelisib ipi million fund novel rd collaboration calico cash flow investing activity reflect capital expenditure net sale purchase shortterm investment capital expenditure include purchase small molecule active pharmaceutical ingredient manufacturing facility singapore abbvie incur additional expenditure build new biologic facility site produce bulk drug substance humira support abbvie biologic pipeline company issue redeem commercial paper balance commercial paper outstanding million million december respectively abbvie issue additional commercial paper retire commercial paper meet liquidity requirement need company issue billion aggregate principal senior note maturity approximately billion net proceed finance acquisition pharmacyclic billion net proceed finance accelerate share repurchase program describe september abbvie enter threeyear billion term loan credit facility day billion term loan credit facility november abbvie draw term facility proceed refinance billion senior note mature connection acquisition pharmacyclic company pay million cost relate billion day bridge term loan credit agreement million cost relate issuance senior note cash dividend payment total billion billion october abbvie announce board director declare increase company quarterly cash dividend share share beginning dividend payable february stockholders record january time declaration payment dividend discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director october abbvie board director authorize billion stock repurchase program march board director authorize billion increase exist stock repurchase program anticipation executing accelerate share repurchase agreement financial institution connection acquisition pharmacyclic abbvie enter execute billion asr morgan stanley co llc morgan stanley pursuant term asr morgan stanley initial delivery approximately million share abbvie common stock represent approximately percent total share expect deliver asr subsequently morgan stanley deliver additional million share abbvie common stock abbvie final settlement asr abbvie record aggregate billion purchase price reduction stockholder equity addition asr company repurchase approximately million share billion open market approximately million share million open market abbvie settle million open market purchase purchase abbvie share program time time management discretion program time limit discontinue time abbvie remain stock repurchase authorization billion december refer note additional information relate asr cash equivalent negatively impact net unfavorable exchange rate change total million million respectively principally weaken euro foreign currency translation company euro denominate asset cash denominate foreign currency abbvie increase concentration cash denominate foreign currency accumulate anticipation terminate propose combination shire significant portion cash equivalent december consider reinveste indefinitely foreign subsidiary abbvie expect reinvestment affect liquidity capital resource fund need operation united states abbvie require accrue pay income taxis repatriate fund abbvie believe sufficient source liquidity support assumption disclose undistribute earning december reinveste indefinitely credit risk abbvie monitor economic condition creditworthiness customer government regulation fund domestically abroad abbvie regularly communicate customer status receivable balance include payment plan obtain positive confirmation validity receivables abbvie establishe allowance account receivable probable collect abbvie monitor potential periodically utilize factoring arrangement mitigate credit risk receivable include arrangement historically material total outstanding receivables abbvie continue business foreign government certain country include greece portugal italy spain experience deterioration credit economic condition substantially abbvie trade receivables greece portugal italy spain governmental health system abbvie continue monitor economic health economy southern europe heighten economic concern exist outstanding net governmental receivables country december follow net receivables year net receivable past million greece portugal italy spain total company continue business foreign government certain oilexporting country experience deterioration economic condition include venezuela saudi arabia outstanding net governmental receivables relate saudi arabia million december refer item quantitative qualitative disclosure market riskforeign currency risk additional disclosure relate venezuela decline price oil liquidity issue certain country result delay collection receivables global economic condition customerspecific factor require company reevaluate collectability receivables company potentially incur credit loss currently abbvie believe economic condition southern europe oilexporte country material impact company liquidity cash flow financial flexibility government funding unavailable country significant adverse change reimbursement practice occur abbvie able collect entire balance outstanding december credit facility access capital credit rating credit facility abbvie currently billion fiveyear revolve credit facility mature october revolve credit facility enable company borrow fund unsecured basis variable interest rate contain covenant december company compliance credit facility covenant commitment fee credit facility material amount outstanding credit facility december access capital company intend fund shortterm longterm financial obligation mature cash hand future cash flow operation issue additional debt company ability generate cash flow operation issue debt enter financing arrangement acceptable term adversely affect material decline demand company product solvency customer supplier deterioration company key financial ratio credit rating material unfavorable change business condition current time company believe sufficient financial flexibility issue debt enter financing arrangement attract longterm capital acceptable term support company growth objective credit rating april follow announcement propose combination pharmacyclic moody investor service confirm baa senior unsecured longterm rating prime shortterm rating revise rating outlook negative stable march standard poor rating service sp affirm abbvie corporate credit rating senior unsecured debt rating commercial paper rating revise rating outlook negative stable additional change company credit rating unfavorable change rating adverse impact future financing arrangement affect company ability draw credit facility result acceleration schedule maturities company outstanding debt contractual obligation follow table summarize abbvie estimate contractual obligation december million total year year year year shortterm borrowing longterm debt capital lease obligation include current portion interest longterm debta future minimum noncancelable operating lease commitment purchase obligation otherb longterm liabilitiesc total include estimate future interest payment longterm debt security capital lease obligation interest payment debt calculate future period interest rate effect end project interest payment include relate effect interest rate swap agreement certain project interest payment differ future base change float interest rate factor event project interest payment pertain obligation agreement outstanding december refer note discussion company debt instrument relate interest rate agreement outstanding december annual interest capital lease obligation material b include company significant unconditional purchase obligation commitment exceed company project requirement normal course business c amount year include voluntary contribution million abbvie main domestic define benefit plan subsequent december amount exclude pension postemployment benefit relate deferred compensation cash outflow time fund uncertain dependent future movement interest rate investment return change law regulation variable include component longterm liability include restructuring refer note information abbvie enter rd collaboration arrangement party require future milestone payment party contingent achievement certain development regulatory commercial milestone individually arrangement material annual reporting period milestone multiple product cover arrangement happen reach reporting period aggregate charge expense material result operation period business perspective payment view positive signify product successfully move development generating likely generate cash flow product sale possible predict reasonable certainty milestone achieve timing achievement result potential payment include table contractual obligation refer note consolidated financial statement discussion collaboration arrangement critical accounting policy estimate preparation financial statement accordance generally accept accounting principle united states require use estimate assumption affect report amount asset liability report amount revenue expense summary company significant accounting policy include note consolidated financial statement certain policy consider critical significantly impact company financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain actual result vary estimate revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer rebate abbvie provide rebate pharmacy benefit manager state government medicaid programs insurance company administer medicare drug plan wholesaler group purchasing organization government agency private entity rebate chargeback accruals record reduction revenue period relate product sell rebate chargeback total billion billion billion respectively rebate amount typically base volume purchase contractual statutory price vary product payer type rebate factor calculation accrual rebate include identification product subject rebate applicable price term estimate lag time sale payment rebate significant order establish rebate chargeback accruals company use internal external datum estimate level inventory distribution channel rebate claim processing lag time type rebate estimate rebate percentage net price company track sale product customer payer company evaluate inventory datum report wholesaler available prescription volume information product pricing historical experience factor order determine adequacy reserve abbvie regularly monitor reserve record adjustment rebate trend rebate program contract term legislative change significant event indicate change reserve appropriate historically adjustment rebate accrual material net earning follow table analysis large rebate accrual chargeback allowance comprise approximately percent total consolidated rebate chargeback charge revenue remain rebate provision charge gross revenue significant determination operating earning medicaid manage medicare care wholesaler millions rebate rebate chargeback balance december provision payment balance december provision payment balance december provision payment balance december cash discount product return allowance cash discount product return total million million million respectively record reduction revenue period relate product sell reserve cash discount readily determinable company experience payment history fairly consistent product return reliably estimate base company historical return experience pension postemployment benefit abbvie engage outside actuary assist determination obligation cost plan direct obligation abbvie valuation fund status net periodic benefit cost plan calculate actuarial assumption significant assumption review annually include discount rate expect longterm rate return plan asset health care cost trend rate significant assumption determine calculation disclose note consolidated financial statement discount rate select base current market rate highquality fixedincome investment december year abbvie employs yieldcurve approach country robust bond market exist yield curve develop highquality bond yield curve approach reflect plan specific cash flow ie duration calculate benefit obligation apply specific spot rate yield curve beginning abbvie reflect plan specific cash flow apply specific spot rate yield curve calculate service cost interest cost portion expense country abbvie review index corporate bond government bond benchmark estimate discount rate abbvie assumed discount rate significant effect amount report define benefit pension postemployment plan december calculation net periodic benefit cost basis point change assume discount rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december basis point million bracket denote reduction increase decrease define benefit plan service cost interest cost project benefit obligation postemployment plan service cost interest cost project benefit obligation effective december abbvie elect change method use estimate service interest cost component net periodic benefit cost abbvie pension plan primary postemployment benefit plan united states certain international define benefit plan postemployment benefit plan base current economic condition change expect reduce abbvie net periodic benefit cost approximately million result change refer note information change expect longterm rate return base asset allocation historical performance current view expect future return abbvie consider input longterm focus avoid shortterm market influence current longterm rate return plan asset support historical performance trust actual target asset allocation abbvie assume expected longterm rate return significant effect amount report define benefit pension plan december calculation net periodic benefit cost percentage point change assume expected longterm rate return plan asset increase decrease net period benefit cost plan million health care cost trend rate select review historical trend current view project future health care cost increase current health care cost trend rate support historical trend experience plan assume health care cost trend rate significant effect amount report health care plan december calculation net periodic benefit cost percentage point change assume health care cost trend rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december percentage point million bracket denote reduction increase decrease service cost interest cost project benefit obligation income taxis abbvie account income taxis asset liability method provision federal state foreign income taxis calculate report pretax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize litigation company subject contingency claim legal proceeding investigation product liability intellectual property commercial security matter arise normal course business refer note information loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency probable range record accordingly abbvie initially unable develop good estimate loss minimum zero record information know minimum loss increase result additional loss provision good estimate result additional loss provision occasionally good estimate change low event result expectation favorable outcome previously expect valuation goodwill intangible asset abbvie acquire continue acquire significant intangible asset connection business combination abbvie record fair value transaction involve purchase sale intangible asset occur frequency company pharmaceutical industry valuation usually base discount cash flow analysis incorporate stage completion discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant factor significantly affect value intangible asset iprd acquire business combination capitalize indefinitelive intangible asset regulatory approval obtain time account definitelived asset amortize estimate useful life iprd acquire transaction business combination expense immediately deem alternative future use payment party subsequent regulatory approval capitalize amortize remain useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable goodwill indefinitelive intangible asset relate iprd review impairment annually event occur result impairment refer note consolidated financial statement information annually company test goodwill impairment assess qualitative factor determine likely fair value carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance sustained decline company share price company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset quantitative impairment test quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate recent accounting pronouncement financial accounting standard board fasb issue accounting standard update asu summary amendment create revenue contract customer topic asset defer costscontract customer subtopic amendment asu supersede current revenue recognition requirement core principal new guidance entity recognize revenue depict transfer promise good service customer reflect consideration entity expect entitled exchange good service abbvie apply amendment follow method retrospectively prior reporting period present ii modify retrospectively cumulative effect initially apply amendment recognize date initial application july fasb issue asu revenue contract customer topic deferral effective date defer effective date asu year entity accordingly asu effective annual reporting period begin december include interim period reporting period early application permit annual reporting period begin december include interim period reporting period abbvie currently assess time adoption impact adopt guidance consolidated financial statement implementation approach april fasb issue asu interestimputation interest subtopic simplify presentation debt issuance cost amendment asu require debt issuance cost relate recognize debt liability present balance sheet direct deduction carry debt liability consistent debt discount standard effective annual interim period begin december early adoption permit retrospective basis abbvie elect early adopt new standard effective month end june result abbvie reclassify approximately million million net deferred financing cost december previously classify prepay expense current asset longterm asset respectively longterm debt lease obligation current noncurrent total debt issuance cost classify reduction longterm debt lease obligation current noncurrent million december september fasb issue asu business combination topic simplify accounting measurementperiod adjustment standard require acquirer recognize adjustment provisional amount identify measurement period report period adjustment amount determined entity currently require retrospectively apply adjustment provisional amount recognize business combination standard effective fiscal year begin december include interim period fiscal year guidance apply prospectively measurement period adjustment occur effective date guidance early application permit financial statement issue abbvie elect early adopt standard effective year end december impact adoption material november fasb issue asu income taxis topic balance sheet classification defer taxis standard require defer tax liability asset classify noncurrent classify statement financial position entity currently require separate defer income tax liability asset current noncurrent amount classify statement financial position amendment require noncurrent presentation jurisdiction effective financial statement issue annual period begin december early application permit begin interim annual reporting period guidance apply prospectively defer tax liability asset retrospectively period present abbvie elect early adopt standard prospective basis effective december order simplify presentation defer tax asset liability prior period retrospectively adjust january fasb issue asu financial instrumentsoverall subtopic recognition measurement financial asset financial liability standard require target change include equity investment account equity method accounting result consolidation investee measure fair value change fair value recognize net income new guidance change certain disclosure requirement aspect current gaap amendment apply cumulativeeffect adjustment balance sheet begin fiscal year adoption standard effective fiscal year start december include interim period fiscal year standard permit early adoption exception certain target provision abbvie currently assess impact timing adopt guidance consolidated financial statement item quantitative qualitative disclosure market risk company expose risk earning cash flow equity adversely impact change foreign exchange rate interest rate certain derivative instrument available costeffective basis hedge company underlie economic exposure refer note entitle financial instrument fair value measure note consolidated financial statement include item financial statement supplementary data information company financial instrument hedge strategy foreign currency risk abbvie primary net foreign currency exposure euro japanese yen british pound abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate transaction denominate currency functional currency local entity contract designate cash flow hedge variability cash flow change foreign currency exchange rate markedtomarket result gain loss reflect accumulated comprehensive income loss abbvie consolidated balance sheet defer gain loss contract include cost product sell time product sell party generally exceed month december abbvie hold billion billion respectively notional amount contract abbvie enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract designate hedge markedtomarket result gain loss reflect net foreign exchange abbvie consolidated statement earning generally offset loss gain foreign currency exposure manage december abbvie hold notional amount billion billion respectively foreign currency forward exchange contract follow table reflect total foreign currency forward contract outstanding december fair fair weighted carrying weight carry average value average value contract exchange receivable contract exchange receivable million rate payable rate payable receive primarily dollar exchange follow currency euro japanese yen british pound currency na na total company estimate percent appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december realize appreciation negatively affect earning remain life contract offset gain underlie hedge item percent appreciation believe reasonably possible nearterm change foreign currency gain loss hedge instrument offset loss gain hedge transaction reduce earning stockholder equity volatility relate foreign exchange functional currency company venezuela operation dollar hyperinflationary status venezuelan economy currency restriction enact venezuela require approval venezuelan government exchange venezuelan bolivar vef dollar require exchange official exchange rate establish government quarter venezuelan government expand number exchange mechanism rate exchange december official rate supplementary system administration foreign currency sicad rate approximately foreign exchange marginal system simadi rate approximately consolidate financial statement year end december company official rate vef dollar report million net monetary asset million net revenue denominate venezuelan bolivar february venezuelan government announce plan devalue official rate vef dollar eliminate sicad rate vef dollar devaluation venezuelan bolivar result charge abbvie result operation quarter abbvie net monetary asset denominate venezuelan bolivar convert rate vef dollar december company report devaluation loss million abbvie net monetary asset denominate venezuelan bolivar convert simadi rate december company report devaluation loss million company predict devaluation venezuelan currency use official rate continue support evolve fact circumstance result significant charge abbvie result operation time interest rate risk interest rate swap manage company exposure change interest rate fair value fixedrate debt effect hedge change fix interest rate variable rate december abbvie interest rate hedge contract total billion billion respectively company estimate increase interest rate basis point decrease fair value interest rate swap contract approximately million december realize fair value reduction affect earning remain life contract company estimate increase basis point longterm interest rate decrease fair value longterm debt billion december basis point change believe reasonably possible nearterm change interest rate market price sensitive investment abbvie hold equity security pharmaceutical biotechnology company trade public stock exchange fair value investment approximately million million december respectively abbvie monitor investment temporary decline market value charge impairment loss net earning temporary decline value occur hypothetical percent decrease share price investment decrease fair value investment million december percent decrease believe reasonably possible nearterm change share price nonpublicly trade equity security abbvie hold equity security pharmaceutical biotechnology company trade public stock exchange carry value investment approximately million million december respectively abbvie monitor investment temporary decline market value charge impairment loss net earning temporary decline estimate value occur abbvie record impairment charge total million relate certain company investment nonpublicly trade equity security item financial statement supplementary datum consolidate financial statement consolidate statement earning consolidate statement comprehensive income consolidate balance sheet consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm abbvie inc subsidiary consolidate statement earning year end december millions share datum net revenue cost product sell sell general administrative research development acquire inprocess research development expense total operating cost expense operate earning interest expense net net foreign exchange loss expense income net earning income tax expense income tax expense net earning share datum basic earning share dilute earning share cash dividend declare common share weightedaverage basic share outstanding weightedaverage dilute share outstanding january cash dividend share common stock declare preseparation earning record reduction additional paidin capital accompany note integral consolidated financial statement abbvie inc subsidiary consolidate statement comprehensive income year end december million net earning foreign currency translation adjustment net tax benefit expense pension postemployment benefit net tax expense benefit unrealize gain marketable equity security net tax expense hedging activity net tax benefit expense comprehensive loss income comprehensive income accompany note integral consolidated financial statement abbvie inc subsidiary consolidate balance sheet december millions share datum asset current asset cash equivalent shortterm investment account receivables net inventory net deferred income taxis prepaid expense total current asset investment property equipment net intangible asset net accumulate amortization goodwill asset total asset liabilitie equity current liability shortterm borrowing current portion longterm debt lease obligation account payable accrue liability total current liability longterm debt lease obligation defer income taxis longterm liability commitment contingency stockholder equity common stock par value authorize share issue share december respectively common stock hold treasury cost share december respectively additional paidincapital retain earning accumulate comprehensive loss total stockholder equity total liability equity accompany note integral consolidated financial statement abbvie inc subsidiary consolidate statement equity accumulate common additional net parent year end share common treasury paidin retain comprehensive company december millions outstanding stock stock capital earning loss investment total balance december separationrelate adjustment reclassification parent company net investment connection separation issuance common share separation net earning comprehensive income net tax dividend declare share repurchase stockbase compensation plan balance december net earning comprehensive loss net tax dividend declare share repurchase stockbase compensation plan balance december net earning comprehensive loss net tax dividend declare common share issue pharrmacyclics inc stockholder share repurchase stockbase compensation plan balance december accompanying note integral consolidated financial statement abbvie inc subsidiary consolidate statement cash flow year end december million bracket denote cash outflow cash flow operating activity net earning adjustment reconcile net earning net cash operating activity depreciation amortization intangible asset stockbase compensation upfront cost milestone relate collaboration net change operate asset liability net acquisition account receivables inventory prepaid expense asset account payable liability cash flow operating activity cash flow invest activity acquisition pharmacyclic inc net cash acquire acquisition investment acquisition property equipment purchase investment security sale maturity investment security cash flow invest activity cash flow financing activity net change shortterm borrowing proceed issuance longterm debt repayment longterm debt capital lease debt issuance cost dividend pay purchase treasury stock proceed exercise stock option net transaction abbott laboratory exclude noncash item net cash flow financing activity effect exchange rate change cash equivalent net increase decrease cash equivalent cash equivalent begin year cash equivalent end year supplemental information interest pay net portion capitalize income taxis pay supplemental schedule noncash investing financing activity issuance common share associate acquisition pharmacyclics inc cash flow operating activity include impact transaction financingrelated cost incur connection terminate propose combination shire plc refer note additional information accompany note integral consolidated financial statement abbvie inc subsidiary note consolidated financial statement note background basis presentation background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse substantially abbvie net revenues united states wholesaler outside united states product sell primarily customer distributor depend market serve abbvie incorporate delaware april january abbvie independent publiclytraded company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder abbvie common stock begin trade regularway ticker symbol abbv new york stock exchange january separationrelate adjustment total billion record stockholder equity separationrelate adjustment additional paidin capital principally reflect dividend abbvie shareholder declare preseparation earning quarter transfer certain pension plan liabilitie asset abbott abbvie legal split plan addition abbvie historical financial statement prior january derive abbott record separationrelate adjustment include adjustment accumulate comprehensive loss reflect appropriate opening balance associate currency translation adjustment relate abbvie legal entity separation date refer note information separation pension plan connection separation abbvie abbott enter transition service agreement cover certain corporate support office service abbvie historically receive abbott services include information technology account payable payroll receivables collection treasury financial function order entry warehousing engineering support quality assurance support administrative service agreement facilitate separation allow abbvie operate independently prior establish standalone office function organization transition service agreement original term month option oneyear extension majority transaction service agreement expire extension december certain limited exception remain transition service agreement terminate prior december year end december abbvie incur million million million respectively separationrelate expense principally classified sell general administrative expense sga consolidated statement earning charge principally relate information technology legal regulatory fee basis historical presentation certain portion abbvie operation legal transfer abbvie asset net liability occur separation abbvie january time require transfer marketing authorization satisfy regulatory requirement certain country term separation agreement abbott abbvie responsible business activity conduct abbott behalf subject risk entitle benefit generate operation asset result related asset liability result operation report abbvie consolidated financial statement year end december net revenue relate operation total approximately million million million respectively exception venezuela operation transfer abbvie december note summary significant accounting policy use estimate financial statement prepare accordance gaap necessarily include amount base estimate assumption management actual result differ amount significant estimate include amount rebate pension post employment benefit income taxis litigation valuation intangible asset goodwill financial instrument inventory account receivable exposure basis consolidation consolidate financial statement year end december include account abbvie subsidiary control interest maintain control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity abbvie determine primary beneficiary investment company abbvie significant influence control interest account equity method abbvie share earning loss report expense income net consolidated statement earning investment generally account cost method intercompany balance transaction eliminate certain reclassification conform prior period consolidated financial statement current period presentation revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer provision discount rebate sale incentive customer return adjustment provide period relate revenue record rebate amount typically base volume purchase contractual statutory price vary product payer type rebate factor calculation accrual rebate include identification product subject rebate applicable price term estimate lag time sale payment rebate significant sale incentive customer material historical datum readily available reliable estimating reduction gross revenue revenue launch new product improve version exist product shipment excess customer normal requirement record condition note meet situation management record return reserve revenue necessary sale product right marketable product record revenue disposition right research development expense internal research development rd expense expense incur clinical trial cost incur party expense contract work perform contingent milestone payment party research development collaboration pre commercialization milestone milestone payment obligation expense milestone result achieve payment party subsequent regulatory approval capitalize intangible asset amortize cost product sell remain useful life relate product collaboration arrangement company enter collaborative agreement party develop commercialize drug candidate collaborative activity include joint research development commercialization new product abbvie generally receive certain licensing right arrangement collaboration require upfront payment include additional milestone research development cost share royalty profit share payment contingent occurrence certain future event link success asset development commercialization upfront payment associate collaborative arrangement development stage expense acquire inprocess research development iprd expense consolidate statement earning subsequent payment partner achievement milestone development stage expense rd expense consolidate statement earning milestone achieve milestone payment partner subsequent regulatory approval capitalize intangible asset amortize cost product sell estimated useful life relate asset royalty expense cost product sell consolidated statement earning incur advertising cost associate advertising expense incur include sga expense consolidate statement earning advertising expense million million million respectively pension postemployment benefit abbvie record annual expense relate define benefit pension postemployment plan base calculation include actuarial assumption include discount rate assume asset rate return compensation increase turnover rate health care cost trend rate abbvie review actuarial assumption annual basis make modification assumption base current rate trend actuarial loss gain amortize remain service attribution period employee corridor method accordance rule account postemployment benefit difference expect longterm return plan asset actual annual return amortize net periodic benefit cost fiveyear period income taxis income taxis account asset liability method provision federal state foreign income taxis calculate report pretax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize cash equivalent cash equivalent include time deposit money market fund original maturity time purchase month investment shortterm investment consist primarily time deposit heldtomaturity debt security investment marketable equity security classify availableforsale record fair value unrealize holding gain loss net tax include accumulate comprehensive loss aoci abbvie consolidated balance sheet investment equity security trade public stock exchange heldtomaturity debt security record cost abbvie review carry value investment quarter determine temporary decline fair value exist abbvie consider factor affect investee factor affect industry investee operate general equity market trend company consider length time investment fair value cost nearterm prospect recovery abbvie determine temporary decline occur cost basis investment write charge expense income net consolidated statement earning availableforsale investment unrealized loss reclassify aoci expense income net consolidated statement earning account receivable account receivable state net realizable value allowance gross account receivable reflect good estimate probable loss inherent receivables portfolio determine basis historical experience specific allowance know troubled account currently available information account receivable write reasonable mean collect include litigation appropriate exhausted allowance million million december respectively inventory inventory value low cost firstin firstout basis market cost include material conversion cost inventory net consist follow december million finish good workinprocess raw material inventory net inventory net december include million acquire acquisition pharmacyclic inc pharmacyclic refer note additional information property equipment december million land building equipment construction progress property equipment gross accumulate depreciation property equipment net depreciation property equipment record straightline basis estimate useful life asset estimate useful life building range year year equipment leasehold improvement amortize life relate facility lease include renewal period appropriate asset whichever short depreciation expense million million million respectively equipment include certain computer software software development cost incur connection develop obtain software internal use amortize year asset capital lease include property equipment consolidate balance sheet material litigation contingency loss contingency provision record probable liability incur liability reasonably estimate base exist information good estimate minimum loss contingency probable range record legal fee expense incur abbvie accrue product liability claim undiscounte basis probable liability incur liability reasonably estimate base exist information liability evaluate quarterly adjust necessary additional information available receivables insurance recovery product liability claim record asset undiscounte basis probable recovery realize business combination result operation acquire company include abbvie result operation begin respective acquisition date asset acquire liability assume recognize date acquisition respective fair value excess fair value consideration transfer estimate fair value net asset acquire recognize goodwill contingent consideration recognize estimate fair value acquisition date determine utilize probability weight discount cash flow model subsequent change fair value contingent payment recognize expense income net consolidated statement earning fair value asset acquire liability assume certain case subject revision base final determination fair value legal cost diligence cost business valuation cost business acquisition cost expense incur goodwill intangible asset intangible asset acquire business combination record fair value discount cash flow model discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant definitelive intangible amortize estimate useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable abbvie compare project undiscounted cash flow generate asset carrying value undiscounte cash flow intangible asset carrying value intangible asset intangible asset write fair value usually discount cash flow loss record equal excess asset net carrying value fair value cash flow identify individual asset review apply low level cash flow largely independent cash flow asset liability goodwill indefinitelive asset amortize subject impairment review annually frequently indicator impairment exist impairment goodwill occur carry reporting unit exceed fair value reporting unit indefinite live intangible asset consist capitalize iprd occur fair value iprd intangible asset carrying company test goodwill impairment assess qualitative factor determine likely fair value carrying company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset quantitative impairment test quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate base company recent annual impairment test perform quarter company conclude goodwill impaired intangible impairment charge record abbvie record impairment charge million relate certain onmarket product right japan increase generic competition charge include cost product sell consolidated statement earning acquire inprocess research development initial cost right iprd project acquire asset acquisition expense iprd consolidated statement earning project alternative future use cost include initial payment incur prior regulatory approval connection research development collaboration agreement provide right develop manufacture market andor sell pharmaceutical product fair value iprd project acquire business combination capitalize account indefinitelive intangible asset underlie project receive regulatory approval point intangible asset account definitelive intangible asset discontinuation point intangible asset write development cost incur acquisition expense incur indefinite definitelive asset subject impairment review discuss previously foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar period end exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive loss income oci consolidate statement comprehensive income net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize net foreign exchange loss consolidate statement earning immaterial year present derivative derivative instrument recognize asset liability fair value abbvie consolidated balance sheet classify current longterm base schedule maturity instrument accounting change fair value derivative instrument depend formally designate qualify hedge relationship applicable accounting standard type hedging relationship derivative formally designate hedge company assess inception quarterly hedge derivative highly effective offset change fair value cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately fair value hedge hedge interest rate risk associate certain company fixedrate debt effective portion change fair value derivative designate cash flow hedge report aoci subsequently recognize earning consistent underlying hedged item cash flow hedge manage exposure change foreign currency exchange rate derivative designate qualify hedge adjust fair value current earning determine derivative long highly effective hedge company discontinue hedge account prospectively gain loss immediately reclassify aoci earning relate hedge forecast transaction long probable occur gain loss relate termination effective cash flow hedge forecast transaction probable occur defer recognize consistent income loss recognition underlie hedged item termination fair value hedge result fair value adjustment hedge item date termination new basis accrete par value date maturity derivative include designate hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item recent accounting pronouncement financial accounting standard board fasb issue accounting standard update asu summary amendment create revenue contract customer topic asset defer costscontract customer subtopic amendment standard supersede current revenue recognition requirement core principal new guidance entity recognize revenue depict transfer promise good service customer reflect consideration entity expect entitled exchange good service abbvie apply amendment follow method retrospectively prior reporting period present ii modify retrospectively cumulative effect initially apply amendment recognize date initial application july fasb issue asu revenue contract customer topic deferral effective date defer effective date asu year entity accordingly standard effective annual reporting period begin december include interim period reporting period early application permit annual reporting period begin december include interim period reporting period abbvie currently assess time adoption impact adopt guidance consolidated financial statement implementation approach april fasb issue asu interestimputation interest subtopic simplify presentation debt issuance cost amendment asu require debt issuance cost relate recognize debt liability present balance sheet direct deduction carry debt liability consistent debt discount standard effective annual interim period begin december early adoption permit retrospective basis abbvie elect early adopt new standard effective month end june result abbvie reclassify approximately million million net deferred financing cost december previously classify prepay expense current asset longterm asset respectively longterm debt lease obligation current noncurrent total debt issuance cost classify reduction longterm debt lease obligation current noncurrent million december september fasb issue asu business combination topic simplify accounting measurementperiod adjustment standard require acquirer recognize adjustment provisional amount identify measurement period report period adjustment amount determined entity currently require retrospectively apply adjustment provisional amount recognize business combination standard effective fiscal year begin december include interim period fiscal year guidance apply prospectively measurement period adjustment occur effective date guidance early application permit financial statement issue abbvie elect early adopt standard effective year end december impact adoption material november fasb issue asu income taxis topic balance sheet classification defer taxis asu require defer tax liability asset classify noncurrent classify statement financial position entity currently require separate defer income tax liability asset current noncurrent amount classify statement financial position amendment require noncurrent presentation jurisdiction effective financial statement issue annual period begin december early application permit begin interim annual reporting period guidance apply prospectively defer tax liability asset retrospectively period present abbvie elect early adopt standard prospective basis effective december order simplify presentation defer tax asset liability prior period retrospectively adjust january fasb issue asu financial instrumentsoverall subtopic recognition measurement financial asset financial liability standard require target change include equity investment account equity method accounting result consolidation investee measure fair value change fair value recognize net income new guidance change certain disclosure requirement aspect current gaap amendment apply cumulativeeffect adjustment balance sheet begin fiscal year adoption standard effective fiscal year start december include interim period fiscal year standard permit early adoption exception certain target provision abbvie currently assess impact timing adopt guidance consolidated financial statement note supplemental financial information interest expense net year end december million interest expense interest income interest expense net interest expense net include million bridge financingrelate cost incur connection acquisition pharmacyclic refer note additional information interest expense net include million financing relate fee incur connection terminate propose combination shire plc company incorporate jersey shire expense income net expense income net include income expense resolution certain contractual agreement impairment equity security gain loss sale equity security expense net primarily consist impairment certain equity security income net primarily consist income million resolution contractual agreement account payable accrue liability december million sale rebate account payable dividend payable salary wage commission royalty license arrangement account payable accrue liability longterm liability december millions pension postemployment benefit liability unrecognize tax benefit longterm liability note earning share abbvie calculate earning share ep dilutive treasury stock twoclass method twoclass method earning allocation formula determine earning share common stock participate security accord dividend declare participation right undistribute earning method earning distribute undistributed allocate common share participate security base respective right receive dividend addition participate security include certain performancebase award exclude calculation ep treasurystock method abbvie forfeitable restrict stock unit rsus restrict stock award rsas include performancebase award participate dividend basis common share dividend nonforfeitable holder declare result forfeitable rsus rsas meet definition participate security period present twoclass method dilutive dilutive effect unvested rsus rsas approximately million million million share respectively exclude denominator calculation dilute eps award include calculation eps treasury stock method additionally earning distribute undistribute allocable participate security include performancebase award include calculation eps treasury stock method exclude numerator calculation basic diluted earning share twoclass method earning allocable participate security million million million respectively describe note abbvie enter execute billion accelerated share repurchase agreement asr morgan stanley co llc morgan stanley pursuant abbvie pay billion initial delivery million share abbvie common stock initial delivery share represent approximately percent total share expect deliver asr morgan stanley subsequently deliver additional million share abbvie common stock abbvie final settlement asr august purpose calculate eps abbvie reflected asr repurchase abbvie common stock number common share issuable stockbase compensation plan exclude computation earning common share effect antidilutive material period present note license acquisition arrangement acquisition pharmacyclic abbvie acquire pharmacyclic tender offer approximately billion include cash consideration billion equity consideration billion pharmacyclic biopharmaceutical company develop commercialize novel therapy people impact cancer pharmacyclic market imbruvica ibrutinib bruton tyrosine kinase btk inhibitor target bcell malignancy outstanding pharmacyclic share exchange cash fair market value abbvie common stock ii cash iii fair market value abbvie common stock election holder subject election proration consideration percent cash percent abbvie common stock total consideration acquisition pharmacyclic approximately billion consist cash approximately million share abbvie common stock summarize follow million fair value abbvie common stock issue pharmacyclic stockholder cash consideration pay pharmacyclic stockholder cash consideration pay pharmacyclic equity award holder total consideration acquisition pharmacyclic account business combination acquisition method accounting method require thing asset acquire liability assume recognize fair value acquisition date valuation asset acquire liability assume acquisition finalize december result abbvie record preliminary estimate fair value asset acquire liability assume acquisition date completion valuation occur later year acquisition date result significant change recognize asset liability follow table summarize preliminary fair value asset acquire liability assume acquisition date million asset acquire liability assume cash equivalent shortterm investment account receivables inventory asset intangible asset definitelive develop product right definitelive license agreement indefinitelive research development account payable accrue liability defer income taxis longterm liability total identifiable net asset goodwill total asset acquire liability assume fair market value stepup adjustment inventory million amortize cost product sell inventory sell customer expect period approximately month acquisition date intangible asset relate imbruvica develop product right iprd united states relate additional indication imbruvica contractual right imbruvica profit loss outside united states result collaboration agreement janssen biotech inc affiliates janssen janssen pharmaceutical companies johnson johnson refer note additional information collaboration janssen acquire definitelive intangible asset amortize weightedaverage estimate useful life year estimate pattern economic benefit estimate fair value iprd identifiable intangible asset determine income approach valuation technique provide estimate fair value asset base market participant expectation cash flow asset generate remain useful life significant assumption inherent development asset valuation include estimate net cash flow year asset product include net revenue cost sale rd cost sell marketing cost work capitalcontributory asset charge appropriate discount rate select order measure risk inherent future cash flow stream assessment asset life cycle potential regulatory commercial success risk competitive trend impact asset cash flow stream factor goodwill calculate excess consideration transfer net asset recognize represent future economic benefit arise asset acquire individually identify separately recognize specifically goodwill recognize acquisition pharmacyclic include expect synergy include ability leverage respective strength business expand combine company product portfolio acceleration clinical commercial presence oncology establishment strong leadership position hematological oncology goodwill deductible tax purpose acquisition date december abbvie consolidated statement earning include net revenue million pretax operating loss million associate acquisition operating loss include million acquisitionrelate compensation expense million inventory stepup intangible asset amortization million transaction integration cost cost million record sga expense million rd expense million cost product sell consolidated statement earning pro forma financial information follow table present unaudited pro forma combine result operation abbvie pharmacyclic acquisition pharmacyclic occur january year end december millions share datum net revenue net earning basic earning share dilute earning share unaudite pro forma financial information prepare acquisition method accounting base historical financial information abbvie pharmacyclic order reflect occurrence acquisition january require unaudited pro forma financial information include adjustment reflect incremental amortization expense incur base current preliminary fair value identifiable intangible asset acquire incremental cost product sell relate fair value adjustment associate acquisitiondate inventory additional interest expense associate issuance debt finance acquisition reclassification acquisition integration financingrelate cost incur year end december year end december unaudited pro forma financial information necessarily indicative consolidated result operation acquisition complete january addition unaudite pro forma financial information projection future result operation combine company reflect expect realization cost saving synergy associated acquisition licensing acquisition activity exclude acquisition pharmacyclic cash outflow related acquisition investment total million million million respectively abbvie record iprd charge million million million respectively abbvie record operating expense million relate collaboration calico life sciences llc calico significant arrangement impact require contingent milestone payment summarize addition significant arrangement describe abbvie enter arrangement result charge iprd million million million connection individually insignificant arrangement enter abbvie additional payment billion achievement certain development regulatory commercial milestone cn diagnostic march abbvie enter exclusive worldwide license agreement cn diagnostic cn develop commercialize antitau antibodie treatment alzheimer disease neurological disorder agreement abbvie initial upfront payment million expense iprd achievement certain development regulatory commercial milestone abbvie additional payment million royaltie net sale calico life sciences llc september abbvie calico enter novel rd collaboration agreement discover develop commercialize new therapy patient agerelate disease include neurodegeneration cancer abbvie record million operate expense consolidated statement earning relate commitment agreement million pay million pay early calico responsible research early development year continue advance collaboration project phase year period abbvie option exclusively license collaboration compound completion phase abbvie support calico early rd effort option exercise responsible latestage development commercial activity collaboration cost profit share equally company post option exercise infinity pharmaceuticals inc september abbvie enter global collaboration agreement infinity pharmaceuticals inc infinity develop commercialize duvelisib ipi treatment patient cancer agreement abbvie initial upfront payment million expense iprd quarter abbvie additional payment million record rd expense consolidated statement earning achievement development milestone collaboration agreement achievement certain development regulatory commercial milestone abbvie additional payment million united states company jointly commercialize duvelisib share equally potential profit outside united states abbvie responsible commercialization duvelisib infinity eligible receive tiere doubledigit royalty net product sale ablynx nv september abbvie enter global collaboration agreement ablynx nv develop commercialize antiilr nanobody alx treatment inflammatory disease include rheumatoid arthritis systemic lupus erythematosus result charge iprd million achievement certain development regulatory commercial milestone abbvie additional payment million royalty net sale galapagos nv september abbvie record charge iprd million result enter global collaboration galapagos nv galapagos discover develop commercialize cystic fibrosis therapy achievement certain development regulatory commercial milestone abbvie additional payment million royalty net sale alvine pharmaceuticals inc abbvie enter global collaboration alvine pharmaceuticals inc develop alv novel oral treatment patient celiac disease agreement abbvie initial upfront payment million expensed iprd second quarter december abbvie additional payment pursuant arrangement activity united therapeutics corporation august abbvie enter agreement purchase rare pediatric disease priority review voucher prv united therapeutics corporation prv entitle abbvie receive fda priority review single new drug application biologic license application reduce target review time lead expedite approval exchange prv abbvie payment million record rd expense consolidate statement earning operating cash outflow consolidate statement cash flow abbvie intend use prv exist rd project termination propose combination shire october abbvie board director withdraw previous recommendation abbvie stockholder favor propose combination shire recommend stockholder vote propose combination october abbvie shire mutually agree terminate propose combination company incur transaction financingrelate cost total billion billion record sga expense million record interest expense net consolidated statement earning include sga expense break fee billion tax deductible pay abbvie shire october result termination propose combination addition company record million net foreign exchange loss primarily undesignated forward contract enter hedge anticipate foreign currency cash outflow associate terminate propose combination shire exit certain foreign currency position forward contract settle quarter abbvie record additional foreign exchange loss million reflect complete liquidation remain foreign currency position refer note information forward contract enter anticipation propose combination shire note collaboration janssen biotech inc december pharmacyclic enter worldwide collaboration license agreement janssen joint development commercialization imbruvica novel orally active selective covalent inhibitor btk certain compound structurally relate imbruvica oncology indication exclude immune inflammatory mediate disease condition psychiatric psychological disease conditions united states outside united states collaboration provide janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states party responsible development manufacturing marketing product generate result collaboration collaboration set duration specific expiration date provide potential future development regulatory approval milestone payment million abbvie collaboration include cost sharing arrangement associate collaboration activity certain case general janssen responsible approximately percent collaboration development cost abbvie responsible remain percent collaboration development cost abbvie janssen share pretax profit loss equally commercialization product janssen responsible exclusive right commercialize imbruvica outside united states party coexclusive right commercialize products united states abbvie principal end customer product sale operating expense cost incur collaboration report respective expense line item net payment reimbursement janssen revenues profit share cost relate sale imbruvica united states include net revenue cost product sell respectively amount payable abbvie janssen imbruvica sale outside united states include net revenue janssen share pretax profit united states collaboration million record cost product sell consolidated statement earning abbvie share pretax profit outside united states cost sharing expense collaboration million million respectively december abbvie receivable janssen million abbvie payable janssen million classify account receivables net account payable accrue liability respectively abbvie consolidated balance sheet note goodwill intangible asset goodwill follow table summarize change carry abbvie goodwill million balance december addition foreign currency translation adjustment balance december addition foreign currency translation adjustment balance december goodwill addition relate acquisition pharmacyclic refer note additional information acquisition late impairment assessment goodwill complete quarter december accumulate goodwill impairment loss future impairment test goodwill perform annually quarter early indicator impairment exist intangible asset net follow table summarize abbvie intangible asset gross net gross net carry accumulate carrying carry accumulate carry december million amortization amortization definitelive intangible asset develop product right license agreement total definitelive intangible asset indefinitelive research development total intangible asset net intangible asset finite useful life amortize estimate useful life range year average year year develop product right license agreement respectively addition primarily acquisition pharmacyclic amount amortize estimate pattern economic benefit refer note additional information acquisition addition primarily relate acquisition million amortizable intangible asset license agreement market product right united states average amortization period year amortization expense million million million respectively include cost product sell consolidated statement earning anticipate annual amortization expense definite live intangible asset record december million million million billion billion quarter impairment charge million record related certain onmarket product right japan increase generic competition charge base discount cash flow analysis include cost product sell consolidated statement earning indefinitelive intangible asset represent acquire iprd associate product receive regulatory approval indefinitelive intangible asset december relate iprd acquire business combination increase primarily acquisition pharmacyclic late impairment assessment intangible asset subject amortization complete quarter impairment charge record impairment charge record related indefinitelive intangible asset material future impairment test indefinitelive intangible asset perform annually quarter early indicator impairment exist note restructuring plan abbvie continuously evaluate operation identify opportunity optimize manufacturing rd operation commercial infrastructure administrative cost respond change business environment example conjunction loss expect loss exclusivity certain product result abbvie management periodically approve individual restructuring plan achieve objective plan individually material restructuring charge record million million million respectively primarily relate employee severance contractual obligation charge record cost product sell rd expense sga expense consolidate statement earning base classification affect employee operation follow summarize cash activity restructuring reserve millions accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december payment adjustment include million reversal previously record restructuring reserve company evaluation prior year decision exit manufacturing facility note debt credit facility commitment contingency follow summary abbvie longterm debt effective effective interest interest rate rate december millions senior note issue float rate note note note note note note senior note issue note note note note note note term loan facility float rate note float rate note fair value hedge unamortized bond discount unamortize deferred financing cost total longterm debt lease obligation current portion noncurrent portion exclude effect related interest rate swap september abbvie enter billion threeyear term loan credit agreement billion day term loan credit agreement collectively term loan facility november abbvie draw term loan facility proceed refinance billion senior note mature november borrowing term loan facility bear interest variable rate adjust base abbvie public debt rating term loan facility prepaid penalty prior notice contain customary covenant company compliance december company issue billion aggregate principal unsecured senior note senior note rank equally unsecured unsubordinated indebtedness company abbvie redeem senior note prior maturity redemption price equal principal senior note redeem plus makewhole premium note abbvie redeem senior note par month prior maturity debt issuance cost incur connection offering total million amortize respective term senior note interest expense net consolidated statement earning senior note contain customary covenant company compliance december approximately billion net proceed issuance senior note finance acquisition pharmacyclic approximately billion net proceed finance asr morgan stanley refer note additional information relate acquisition pharmacyclic asr respectively march abbvie enter billion day bridge term loan credit agreement bridge loan support plan acquisition pharmacyclic amount draw bridge loan terminate result company issuance senior note interest expense net include million cost relate bridge loan abbvie outstanding billion aggregate principal unsecured senior note issue abbvie redeem senior note series time senior note series time time redemption price equal principal senior note redeem plus makewhole premium december company compliance senior note covenant shortterm borrowing december shortterm borrowing include million million respectively commercial paper borrowing weightedaverage interest rate shortterm borrowing percent percent respectively october abbvie enter billion fiveyear revolve credit facility mature october replace billion year revolve credit facility revolve credit facility enable company borrow fund unsecured basis variable interest rate contain covenant december company compliance credit facility covenant commitment fee abbvie revolve credit facility material amount outstanding credit facility december december maturities longterm debt capital lease obligation follow table summarize abbvie future minimum lease payment noncancelable operating lease debt maturity future minimum lease payment capital lease obligation december debt maturity operate capital year end december million lease lease total obligation commitment fair value hedge unamortized bond discount defer financing cost total debt lease obligation lease expense million million million abbvie operating lease generally include renewal option provide company pay taxis maintenance insurance operating cost lease property december annual future minimum lease payment capital lease obligation material debt maturity capital lease include billion float rate note draw day term loan credit agreement contingency guarantee connection separation abbvie indemnify abbott liability result operation abbvie business income tax liability respect period prior distribution date liability agree abbvie abbott abbvie material exposure offbalance sheet arrangement specialpurpose entity activity include nonexchangetrade contract account fair value ordinary course business abbvie periodically enter thirdparty agreement assignment product right result abbvie secondarily liable obligation abbvie previously primarily liable base past experience likelihood payment agreement remote abbvie periodically acquire business product right abbvie agree pay contingent consideration base attain certain threshold base occurrence certain future event note financial instrument fair value measure risk management policy company expose foreign currency exchange rate interest rate risk relate business operation company hedge policy attempt manage risk acceptable level base company judgment appropriate tradeoff risk opportunity cost company use derivative instrument reduce exposure foreign currency exchange rate company expose risk earning cash flow adversely impact fluctuation interest rate company periodically enter interest rate swap base judgment manage interest cost company agree exchange specify interval difference fix float interest amount calculate reference agreedupon notional derivative instrument trading purpose manage exposure change interest rate investment security company outstanding derivative instrument contain credit risk relate contingent feature collateral generally require financial instrument abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate intercompany transaction denominate currency functional currency local entity contract notional amount total billion billion december december respectively designate cash flow hedge record fair value result gain loss reflect oci accumulate gain loss december reclassify aoci include cost product sell time product sell generally exceed month company enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract designate hedge record fair value result gain loss reflect net foreign exchange loss consolidate statement earning generally offset loss gain foreign currency exposure manage december december abbvie hold notional amount billion billion respectively undesignated foreign currency forward exchange contract company enter undesignated forward exchange contract total notional billion hedge anticipate foreign currency cash outflow associate terminate propose combination shire large portion contract originally mature quarter net settle fourth quarter company realize million net foreign exchange loss associate shirerelate forward exchange contract abbvie party interest rate hedge contract designate fair value hedge total billion billion december december respectively effect hedge change fixedrate interest obligation float rate portion debt abbvie record contract fair value adjust carrying fixedrate debt offset follow table summarize amount location abbvie derivative instrument consolidate balance sheet fair valuederivative asset position fair valuederivative liability position balance sheet december million caption balance sheet caption foreign currency forward exchange contract hedge instrument prepaid expense account payable accrue liability designate hedge prepay expense account payable accrue liability interest rate swap designate prepay expense fair value hedge longterm liability total derivative certain derivative subject netting arrangement company counterpartie company offset derivative asset liability consolidated balance sheet unrealize gainslosse effective portion derivative instrument designate cash flow hedge recognize oci million million million respectively hedge ineffectiveness significant year present follow table summarize pretax amount location consolidated statement earning net gainslosse recognize consolidated statement earning derivative instrument include effective portion net gainslosse reclassify aoci net earning respectively note net gainslosse reclassify aoci year end december million statement earning caption foreign currency forward exchange contract designate cash flow hedge cost product sell designate hedge net foreign exchange loss interest rate swap designate fair value hedge interest expense net total gainloss relate fair value hedge recognize interest expense net consolidated statement earning directly offset lossgain underlying hedged item fixedrate debt result net impact interest expense net period present fair value measure fair value hierarchy accounting standard fair value measurement consist follow level level valuation base unadjusted quote price active market identical asset company ability access level valuation base quote price similar instrument active market quote price identical similar instrument market active modelbase valuation significant input observable market level valuation significant input unobservable market include use judgment company management assumption market participant use price asset liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price significant active market significant observable unobservable identical asset input input million total level level level asset cash equivalent time deposit equity security interest rate hedge foreign currency contract total asset liabilitie interest rate hedge foreign currency contract total liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price significant active market significant observable unobservable identical asset input input million total level level level asset cash equivalent time deposit equity security foreign currency contract total asset liabilitie interest rate hedge foreign currency contract total liability fair value time deposit include cash equivalent shortterm investment determine base discount cash flow analysis reflect quote market rate similar instrument fair value time deposit approximate amortized cost short maturity instrument availableforsale equity security consist investment fair value determine publish market price unit multiply number unit hold consideration transaction cost derivative enter company value publicize spot curve interest rate hedge publicize forward curve foreign currency contract cumulative net unrealized holding gain availableforsale equity security total million million december december respectively transfer asset liability fair value measurement level addition financial instrument company require recognize fair value consolidate balance sheet company certain financial instrument recognize historical cost basis fair value carry value fair value certain financial instrument summarize table approximate book value fair value december million asset investment liability shortterm borrowing current portion longterm debt lease obligation longterm debt lease obligation exclude fair value hedge follow table summarize basis measure approximate fair value financial instrument december basis fair value measurement quote price significant active market significant observable unobservable identical asset input input million total level level level asset investment total asset liability shortterm borrowing current portion longterm debt lease obligation longterm debt lease obligation exclude fair value hedge total liability follow table summarize basis measure approximate fair value financial instrument december basis fair value measurement quote price active significant market significant identical observable unobservable asset input input million total level level level asset investment total asset liability shortterm borrowing current portion longterm debt lease obligation longterm debt lease obligation exclude fair value hedge total liability investment consist cost method investment heldtomaturity debt security determine fair value cost method investment company take consideration recent transaction financial information investee represent level basis fair value measurement fair value heldtomaturity debt security estimate base quote market price similar debt instrument fair value shortterm current borrowing approximate carry value short maturity instrument fair value longterm debt exclude fair value hedge term loan determine publish market price debt instrument consideration transaction cost represent level basis fair value measurement fair value term loan determine base discount cash flow analysis quote market rate represent level basis fair value measurement counterpartie financial instrument consist select major international financial institution concentration risk company invest excess cash time deposit money market fund diversify concentration cash different financial institution company monitor concentration credit risk associate deposit financial institution credit exposure limit establish limit concentration single issuer institution functional currency company venezuela operation dollar hyperinflationary status venezuelan economy currency restriction enact venezuela require approval venezuelan government exchange venezuelan bolivar vef dollar require exchange official exchange rate establish government quarter venezuelan government expand number exchange mechanism rate exchange december official rate supplementary system administration foreign currency sicad rate approximately foreign exchange marginal system simadi rate approximately consolidate financial statement year end december company official rate vef dollar report million net monetary asset million net revenue denominate venezuelan bolivar february venezuelan government announce plan devalue official rate vef dollar eliminate sicad rate vef dollar devaluation venezuelan bolivar result charge abbvie result operation quarter abbvie net monetary asset denominate venezuelan bolivar convert rate vef dollar december company report devaluation loss million abbvie net monetary asset denominate venezuelan bolivar convert simadi rate december company report devaluation loss million company predict devaluation venezuelan currency use official rate continue support evolve fact circumstance result significant charge abbvie result operation time company continue business foreign government certain oilexporting country include venezuela saudi arabia experience deterioration economic condition decline price oil liquidity issue certain country result delay collection receivable wholesaler account percent percent total net account receivable december december respectively substantially abbvie net revenues united states wholesaler addition net governmental receivables outstanding greece portugal italy spain total million december million december humira adalimumab abbvie single large product account approximately percent percent percent abbvie total net revenue respectively note postemployment benefit abbvie sponsor pension postemployment benefit plan include define benefit define contribution termination indemnity plan cover employee worldwide addition abbvie provide medical benefit primarily eligible retiree united states puerto rico postretirement benefit plan net obligation plan reflect consolidated balance sheet december abbvie principal domestic define benefit plan abbvie pension plan abbvie employee eligible participate abbott pension plan december automatically eligible abbvie pension plan quarter abbvie pension plan assume obligation relate asset abbvie employee abbott abbvie voluntary contribution million million million respectively plan abbvie voluntary contribution million plan subsequent december benefit plan information table pertain global abbviesponsore define benefit postemployment plan define postemployment benefit plan plan year end december millions project benefit obligation begin period service cost interest cost employee contribution plan amendment actuarial gain loss benefit pay primarily foreign currency translation adjustment end period fair value plan asset begin period actual loss return plan asset company contribution employee contribution benefit pay primarily foreign currency translation adjustment end period fund status end period amount recognize consolidated balance sheet noncurrent asset account payable accrue liability longterm liability net obligation actuarial loss net prior service cost accumulate comprehensive loss december project benefit obligation pbo table include billion billion december respectively relate international define benefit plans number generally fund permit local regulation benefit payment plan fund company asset abbvie consider release new mortality table projection scale society actuary determine improvement estimate future mortality opt change new table determine fund status december society actuary release improvement scale adjust previously issue scale abbvie determine appropriate utilize determine fund status december plan reflect table accumulate benefit obligation abo billion billion december respectively plan reflect table abo exceed plan asset december abo pbo aggregate plan asset billion billion billion respectively amount recognize accumulate comprehensive loss comprehensive loss income define benefit postemployment plan actuarial gain loss prior service cost credit recognize net periodic benefit cost include aoci net tax amortize net periodic benefit cost future period follow table summarize pretax gain loss include comprehensive loss income year end december millions define benefit plan actuarial gain loss prior service cost amortization actuarial loss prior service cost foreign exchange gain loss total pretax gain loss recognize comprehensive income loss postemployment plan actuarial gain loss prior service cost amortization actuarial loss prior service cost total pretax gain loss recognize comprehensive income loss pretax actuarial loss prior service cost include aoci december expect recognize net periodic benefit cost million define benefit plan million postemployment plan net periodic benefit cost year end december millions define benefit plan service cost interest cost expect return plan asset amortization actuarial loss prior service cost net periodic benefit cost postemployment plan service cost interest cost amortization actuarial gain loss prior service cost net periodic benefit cost weightedaverage assumption determine benefit obligation measurement date december define benefit plan discount rate rate compensation increase postemployment plan discount rate assumption calculate december measurement date benefit obligation calculation net periodic benefit cost weightedaverage assumption determine net periodic benefit cost year end december define benefit plan discount rate expect longterm rate return plan asset expect rate change compensation postemployment plan discount rate effective december abbvie elect change method use estimate service interest cost component net periodic benefit cost abbvie pension plan primary postemployment benefit plan united states certain international define benefit plan postemployment benefit plan historically abbvie estimate service interest cost component expense utilize single weightedaverage discount rate derive yield curve measure benefit obligation beginning period late abbvie elect utilize yield curve approach estimation component apply specific spot rate yield curve determination benefit obligation relevant project cash flow abbvie elect change provide precise measurement service interest cost improve correlation project benefit cash flow correspond spot yield curve rate abbvie account change prospectively change accounting estimate inseparable change accounting principle base current economic condition change expect reduce abbvie net periodic benefit cost approximately million change effect expense affect measurement abbvie total benefit obligation change service cost interest cost completely offset actuarial gain loss report purpose measure postretirement health care obligation measurement date company assume percent pre percent post annual rate increase capita cost cover health care benefit rate assume decrease gradually percent remain level purpose measure postretirement health care cost company assume percent pre percent post annual rate increase capita cost cover health care benefit rate assume decrease gradually percent remain level assume health care cost trend rate significant effect amount report health care plan december percentage point change assume health care cost trend rate follow effect percentage point year end december million bracket denote reduction increase decrease service cost interest cost project benefit obligation define benefit pension plan asset basis fair value measurement quote price significant active market significant observable unobservable identical asset input input december millions level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real asset otherf fair value plan asset basis fair value measurement quote price significant active market significant observable unobservable identical asset input input december millions level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real asset otherf fair value plan asset mix pool index fund actively manage equity account benchmarke large cap index b mix pool index fund actively manage equity account benchmarke mid cap index c mix pool index fund actively manage equity account benchmarke nonus equity index develop emerge market security hold actively manage account pool index fund mutual fund e fund global mandate flexibility allocate capital broadly wide range asset class strategy include limited equity fix income commodity financial future currency security objective outperform agree benchmark specific return volatility target f investment cash cash equivalent equity value quote price value publish market price equitie common collective trust register investment company value significant observable input value net asset value nav provide fund administrator nav base value underlie asset own fund minus liability fix income security value significant observable input value price obtain independent financial service industryrecognize vendor absolute return fund commodity value nav provide fund administrator follow table summarize change value plan asset measure significant unobservable input level year end december millions beginning period actual return plan asset hand end period purchase sale settlement net end period investment mix equity security fix income asset allocation strategy base achieve desire return balance high return volatile equity security low return volatile fix income security investment allocation establish plan generally range market industry sector capitalization size case fix income security maturity credit quality target investment allocation abbvie pension plan percent equity security percent fix income security percent asset allocation strategy holding know significant concentration risk plan asset abbvie pension plan plan asset plan expect return plan asset assumption show base management expectation longterm average rate return achieve underlie investment portfolio establish assumption management consider historical expect return asset class plan invest current economic capital market condition expect define benefit postemployment plan payment define post benefit employment year end december million plan plan table reflect total benefit payment expect pay participant include payment fund company asset pay plan abbvie principal define contribution plan abbvie saving plan abbvie record expense million million million relate plan abbvie provide certain postemployment benefit primarily salary continuation arrangement qualify employee accrue related cost service live employee note equity stockbased compensation stockbase compensation expense million million million respectively principally classify sga period present remainder classify rd expense cost product sell related tax benefit recognize million million million respectively compensation expense stockbase award measure base fair value award date stockbase award grant adjust estimate number award expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate compensation cost stockbase award amortize service period shorter vest period employee retirement eligible charge compensation expense stockbase award grant retirementeligible employee compensation expense recognize immediately grant date employee able retain award continue provide service retirement eligible employee generally age year service prior separation abbvie employee participate abbott incentive stock program abbvie incentive stock program adopt time separation facilitate assumption certain award grant abbott incentive stock program authorize postseparation grant different form benefit include nonqualified stock option rsas rsus performancebase rsas rsus abbvie incentive stock program million share common stock reserve issuance respect postseparation award participant connection separation outstanding abbott employee stock option rsas rsus previously issue abbott incentive stock program adjust convert new abbott abbvie stockbase award formula design preserve intrinsic value fair value award immediately prior separation separation january holders abbott stock option rsas rsus generally receive abbvie stockbased award abbott stockbased award outstanding adjust award retain vest schedule expiration date original award abbvie award grant abbott employee connection separation realize excess tax benefit associate stockbase compensation record additional paidin capital total million million million respectively present consolidated statement cash flow outflow operating activity inflow financing activity stock option exercise price option grant equal percent fair value date grant stock option typically contractual term year generally vest onethird increment threeyear period fair value stock option determine blackschole model weightedaverage grantdate fair value stock option grant respectively stockbase compensation expense attributable option year present material follow table summarize abbvie stock option activity weight weight average average remain aggregate year end december exercise life intrinsic option thousand aggregate intrinsic value million option price year value outstanding beginning period grant exercise lapsed outstanding end period exercisable end period aggregate intrinsic value table represent difference exercise price company closing share price day trading total intrinsic value option exercise million million million respectively total fair value option vest million rsas rsus rsas rsus generally vest onethird increment year vest recipient receive share common stock vested award abbvie grant performancebase rsas rsus select executive key employee vest primarily contingent abbvie achieve minimum return equity fair value rsas rsus include performancebase award determine base number share grant quote price abbvie common stock date grant purpose determine compensation expense abbvie periodically evaluate performance goal achieve goal meet compensation expense recognize previously recognize compensation expense reverse follow table summarize abbvie rsa rsu activity include performancebase award abbvie abbott employee weight average share grant date fair year end december share unit thousand unit value outstanding beginning period grant vested lapsed outstanding end period fair market value rsas rsus vest million million million respectively december million unrecognized compensation cost relate rsas rsus expect recognize expense approximately year cash dividend february august november abbvie pay quarterly cash dividend share common stock respectively declare board director october february june september respectively dividend declare october february represent increase nearly percent approximately percent respectively previous quarterly rate share share respectively october company announce board director declare increase company quarterly cash dividend share share beginning dividend payable february stockholders record january reflect increase approximately percent previous quarterly rate february august november abbvie pay quarterly cash dividend share common stock respectively declare board director december february june september respectively stock repurchase program february abbvie board director authorize billion stock repurchase program october abbvie board director authorize new billion stock repurchase program effective immediately supersede previous authorization current stock repurchase authorization permit purchase abbvie share time time open market private transaction management discretion depend company cash flow net debt level market condition program time limit discontinue time march board director authorize billion increase exist stock repurchase program anticipation executing accelerate share repurchase agreement connection acquisition pharmacyclic abbvie enter execute billion asr morgan stanley pursuant term asr morgan stanley initial delivery approximately million share abbvie common stock represent approximately percent total share expect deliver asr morgan stanley subsequently deliver additional million share abbvie common stock abbvie final settlement asr abbvie record aggregate billion purchase price reduction common stock hold treasury consolidated balance sheet december addition asr abbvie repurchase approximately million share million share million share billion million million respectively open market abbvie settle million open market purchase share repurchase program record acquisition cost include related expense available general corporate purpose abbvie remain share repurchase authorization billion december accumulate comprehensive loss follow table summarize change component aoci net tax unrealized gain foreign pension loss currency post marketable translation employment equity hedging millions bracket denote loss adjustment benefit security activity total balance december comprehensive income loss reclassification net loss reclassify accumulated comprehensive loss net currentperiod comprehensive income loss separationrelate adjustment balance december comprehensive loss income reclassification net loss reclassify accumulated comprehensive loss net currentperiod comprehensive loss income balance december comprehensive income reclassification net loss gain reclassify accumulated comprehensive loss net currentperiod comprehensive loss income balance december comprehensive loss include foreign currency translation adjustment total loss billion principally drive impact substantial weakening euro translation company eurodenominate asset ii weaken foreign currency combination increase concentration cash denominate foreign currency accumulate anticipation terminate propose combination shire plc comprehensive loss include foreign currency translation adjustment total loss million principally drive impact continue weaken euro translation company eurodenominate asset table present impact abbvie consolidated statement earning significant amount reclassify component accumulate comprehensive loss year end december million bracket denote gain pension postemployment benefit amortization actuarial loss othera tax benefit total reclassification net tax hedging activity gain loss designate cash flow hedgesb tax expense benefit total reclassification net tax amount include computation net periodic benefit cost note b amount include cost product sell note addition common stock abbvie authorize capital include million share prefer stock par value december share prefer stock issue outstanding note income taxis earning income tax expense year end december million domestic foreign total earning income tax expense domestic loss income taxis drive transaction financingrelate cost associate terminate propose combination shire refer note information income tax expense year end december million current domestic foreign total current taxis defer domestic foreign total defer taxis total income tax expense effective tax rate reconciliation year end december statutory tax rate state taxis net federal benefit effect foreign operation tax credit brand prescription drug fee valuation allowance net effective tax rate effective tax rate fluctuate year year allocation company taxable earning jurisdiction certain discrete factor event year include acquisition collaboration effective tax rate differ statutory tax rate principally benefit foreign operation reflect impact low income tax rate location outside united states tax exemption incentive puerto rico foreign tax jurisdiction business development activity cost repatriation decision effective tax rate period reflect benefit tax credit principally relate research development credit orphan drug tax credit puerto rico excise tax credit research development credit legislation enact fourth quarter year retroactively extend credit puerto rico excise tax credit relate legislation enact puerto rico assess excise tax begin certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell consolidated statement earning majority tax creditable income tax purpose effective income tax rate include tax benefit million reduction state valuation allowance effective tax rate include additional expense million relate brand prescription drug fee nondeductible state valuation allowance million july internal revenue service issue final rule regulation brand prescription drug fee annual nontaxdeductible fee payable federal government affordable care act base allocation company market share brand prescription drug sell certain government program prior year final rule accelerate expense recognition criterion fee obligation year fee pay year market share allocate fee determine change require abbvie industry participant recognize additional year expense effective income tax rate reflect income tax expense relate current earning outside united states deem indefinitely reinveste defer tax asset liability december millions defer tax asset compensation employee benefit accrual reserve chargeback rebate defer revenue depreciation net operating loss credit carryforward total defer tax asset valuation allowance total net defer tax asset defer tax liability excess book basis tax basis intangible asset excess book basis tax basis investment total defer tax liability net defer tax liability asset increase defer tax liability primarily acquisition pharmacyclic abbvie record excess book basis tax basis intangible asset investment gross federal net operating loss tax credit carryforward december million million respectively available use gross state net operating loss tax credit carryforward december billion million respectively state tax carryforward expire december foreign net operating loss carryforward million foreign net operating loss carryforward million expire remain expiration period december company valuation allowance million million respectively principally relate state net operating loss credit carryforward expect realize deferred income taxis provide approximately billion undistributed earning foreign subsidiary earning indefinitely reinveste continued use foreign operation complexity tax law assumption practicable estimate income taxis earning distribute unrecognized tax benefit year end december million balance january increase current year tax position increase prior year tax position decrease prior year tax position lapse statute limitation separationrelate adjustment balance december abbvie abbott enter tax sharing agreement effective date separation provide abbott liable indemnify abbvie income tax liability period prior separation abbvie responsible unrecognized tax benefit relate interest penalty period separation instance exist entity transfer abbvie separation table reflect reduction billion relate tax period prior separation abbott primary obligor treasury regulation member consolidated group severally liable federal income tax liability member consolidated group accordingly respect periods abbvie include abbott consolidated group abbvie liable government federal income tax liability incur consolidated group extent discharge member liability impose abbvie entitle indemnify abbott pursuant tax sharing agreement recognize net potential tax benefit impact company effective tax rate million million respectively unrecognized tax benefit record table december abbvie indemnify approximately million increase prior year tax position table include amount relate federal state international item prior position acquire business development activity year uncertain tax position generally include longterm liability consolidated balance sheet abbvie recognize interest penalty relate income tax matter income tax expense abbvie recognize gross income tax expense million million million respectively interest penalty relate income tax matter december abbvie million million million accrue payment gross interest penalty company routinely audit tax authority significant jurisdiction number audits currently underway reasonably possible month uncertain tax position settle result decrease gross unrecognized tax benefit potential resolution federal state foreign examination expiration statute limitation company gross unrecognized tax benefit balance change month million significant federal state local international matter conclude year company believe adequate provision income tax uncertainty note legal proceeding contingency abbvie subject contingency claim legal proceeding investigation product liability intellectual property commercial security matter arise normal course business loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency probable range record record accrual balance litigation december million december significant initiation new legal proceeding change status exist proceeding result change estimate loss accrue abbvie feasible predict outcome proceeding exposure certainty management believe ultimate disposition material adverse effect abbvie consolidated financial position result operation cash flow subject certain exception specify separation agreement abbott abbvie abbvie assume liability control pende threatened legal matter relate business include liability claim legal proceeding relate product business discontinue prior distribution assume retain liability indemnify abbott liability arise result assume legal matter pende lawsuit file unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquire february know abbvie product llc consolidated pretrial purpose united states district court northern district georgia multidistrict litigation mdl rules androgel antitrust litigation mdl case bring private plaintiff federal trade commission ftc generally allege solvay patent litigation involve androgel sham litigation patent litigation settlement agreement relate agreement generic company violate federal state antitrust law state consumer protection unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee mdl include individual plaintiff lawsuit b purport class action c federal trade commission v watson pharmaceuticals inc et al follow district court dismissal plaintiff claim appellate proceeding lead reinstatement claim patent litigation settlement proceeding discovery district court attorney general state alaska serve abbvie civil investigative demand primarily seek document abbvie produce lawsuit november glaxosmithkline plc gsk file lawsuit abbott united states district court northern district california allege abbott violate federal antitrust state law connection norvir reprice march jury find abbott violate antitrust law breach license agreement gsk january united states court appeals ninth circuit reverse verdict remand case new trial alleged improper exclusion potential juror case return district court california gsk dismiss federal antitrust claim case transfer april united states district court middle district north carolina pretrial proceeding pende abbvie assume liability control proceeding connection separation abbott lawsuit pende abbvie generally allege patent litigation settlement involve niaspan enter kos pharmaceuticals inc company acquire abbott presently subsidiary abbvie generic company violate federal state antitrust law state unfair deceptive trade practice unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee lawsuit consist individual plaintiff lawsuit consolidated purport class action bring name direct purchaser niaspan bring name endpayor purchaser niaspan case consolidate pretrial proceeding united states district court eastern district pennsylvania mdl rule niaspan antitrust litigation mdl office attorney general state alaska serve abbvie civil investigative demand primarily seek document abbvie produce lawsuit september ftc file suit united states district court eastern district pennsylvania abbvie allege patent litigation generic company androgel sham litigation patent litigation settlement generic company violate federal antitrust law ftc complaint seek monetary damage injunctive relief court dismiss ftc claim patent litigation settlement office attorney general state alaska serve abbvie civil investigative demand primarily seek document abbvie produce lawsuit march state louisiana file lawsuit state louisiana v fournier industrie et sante et al abbvie abbott affiliate abbott entities louisiana state court plaintiff allege patent application patent litigation file allege conduct early related drug tricor violate louisiana state antitrust unfair trade practice law lawsuit seek monetary damage attorney fee august court dismiss case timebarre state appeal dismissal pende august putative class action lawsuit sidney hillman health center rochester et al v abbvie inc et al file abbvie united states district court northern district illinois healthcare benefit provider allege violation federal racketeer influence corrupt organization rico statute state deceptive business practice unjust enrichment law connection reimbursement certain use depakote plaintiff seek monetary damage andor equitable relief attorney fee november putative class action lawsuit medical mutual ohio v abbvie inc et al file manufacturer testosterone replacement therapie trt include abbvie united states district court northern district illinois behalf insurance company health benefit provider party payor pay trt include androgel claim assert include violation federal rico act state consumer fraud deceptive trade practice law complaint seek monetary damage injunctive relief similar lawsuit ally service division welfare fund v abbvie inc et al file court october behalf putative class member putative class consumer product liability case pende plaintiff generally allege abbvie manufacturer trt adequately warn risk certain injury primarily heart attack stroke blood clot approximately claim consolidated pretrial purpose united states district court northern district illinois mdl rule testosterone replacement therapy product liability litigation mdl approximately claim pende state court plaintiff seek compensatory punitive damage product liability case pende plaintiff generally allege abbvie adequately warn risk certain injury primarily birth defect arise use depakote ninety percent approximately claim pende united states district court southern district illinois rest pende federal state court plaintiff seek compensatory punitive damage november individual file putative class action lawsuit behalf purchaser seller certain shire securities june october abbvie chief executive officer united states district court northern district illinois allege defendant andor responsible material misstatement violation federal security law connection abbvie propose transaction shire complaint seek monetary damage injunctive relief december shareholder derivative lawsuit plumber steamfitter local pension plan v jp morgan securities llc et al file delaware chancery court allege abbvie director breach fiduciary duty connection approval termination abbvie propose transaction shire lawsuit seek monetary damage abbvie relief note segment geographic area information abbvie operate business segmentpharmaceutical product substantially abbvie net revenues united states wholesaler outside united states product sell primarily health care provider distributor depend market serve follow table detail abbvie worldwide net revenue year end december millions humira imbruvica viekira creon synagis lupron synthroid kaletra androgel sevoflurane duodopa dyslipidemia product total net revenue net revenue external customer geographic area base product shipment destination follow year end december millions united states germany united kingdom spain japan france canada italy brazil netherlands country total net revenue longlive asset include net property equipment billion billion december billion billion respectively locate united states puerto rico million million respectively locate europe note quarterly financial datum unaudite million share datum quarter net revenue gross margin net earningsa basic earning share dilute earning share cash dividend declare common share second quarter net revenue gross margin net earningsb basic earning share dilute earning share cash dividend declare common share quarter net revenue gross margin net earningsc basic earning share dilute earning share cash dividend declare common share fourth quarter net revenuesd gross margind net earning losse basic earning loss share f dilute earning loss share f cash dividend declare common share result quarter include aftertax foreign exchange loss million relate liquidation remain foreign currency position relate terminate propose combination shire million aftertax charge result enter exclusive worldwide license agreement cn aftertax cost million incur connection acquisition pharmacyclic b second quarter result include aftertax cost total million incur connection acquisition integration pharmacyclic second quarter result include aftertax charge million relate regulatory milestone collaboration partner regulatory milestone relate company hcv program c result quarter include million aftertax charge relate purchase rare pediatric disease prv united therapeutics corporation aftertax cost total million incur connection acquisition integration pharmacyclic million aftertax charge achievement development milestone global collaboration infinity quarter result include million aftertax charge result enter global collaboration infinity million aftertax charge relate research development collaboration agreement calico transaction financingrelate cost aggregate million aftertax incur connection terminate propose combination shire refer note information relate termination propose combination shire collaboration calico infinity net revenue gross margin include milestone revenue million collaboration partner relate company oncology program net revenue gross margin include royalty income million relate prior period result settlement licensing arrangement e fourth quarter result include aftertax cost total million incur connection acquisition integration pharmacyclic aftertax charge million increase company litigation reserve result fourth quarter include aftertax transaction financingrelated cost incur connection terminate propose combination shire aggregate billion million aftertax charge relate research development collaboration agreement calico f basic loss share fourth quarter calculate treasurystock method dilutive approximately million common share exclude computation dilute loss share assume dilution effect antidilutive report independent register public accounting firm board director shareholders abbvie inc audit accompany consolidated balance sheet abbvie inc subsidiary december relate consolidated statement earning comprehensive income equity cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position abbvie inc subsidiary december consolidate result operation cash flow year period end december conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states abbvie inc subsidiary internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon ernst young llp chicago illinois february item change disagreement accountant account financial disclosure item control procedure disclosure control procedure evaluation disclosure control procedure chief executive officer richard gonzalez chief financial officer william j chase evaluate effectiveness abbvie disclosure control procedure end period cover report conclude abbvie disclosure control procedure effective ensure information abbvie require disclose report file submit securities exchange commission securities exchange act record process summarize report time period specify commission rule form ensure information require disclose abbvie report file submit securities exchange act accumulate communicate abbvie management include principal executive officer principal financial officer appropriate allow timely decision require disclosure internal control financial reporting management annual report internal control financial reporting management report internal control financial reporting include hereof report abbvie independent register public accounting firm relate assessment effectiveness internal control financial reporting include hereof change internal control financial reporting separation abbott abbvie begin phase global implementation new enterprise resource planning system relate technology infrastructure transaction processing service replace information technology infrastructure transactional service provide abbvie abbott transition service agreement initiative complete include modification design operation control financial reporting abbvie review control design effectiveness prior implementation phase change abbvie internal control financial reporting define rule af securities exchange act materially affect reasonably likely materially affect abbvie internal control financial reporting quarter end december inherent limitation effectiveness control abbvie management include chief executive officer chief financial officer expect abbvie disclosure control internal control financial reporting prevent detect error fraud control system matter design operate provide reasonable absolute assurance control system objective meet design control system reflect fact resource constraint benefit control consider relative cost inherent limitation control system evaluation control provide absolute assurance misstatement error fraud occur control issue instance fraud detect inherent limitation include reality judgment decisionmake faulty breakdown occur simple error mistake control circumvent individual act person collusion people management override control design system control base certain assumption likelihood future event assurance design succeed achieve state goal potential future condition projection evaluation control effectiveness future period subject risk time control inadequate change condition deterioration degree compliance policy procedure item b information management report internal control financial reporting management abbvie responsible establish maintain adequate internal control financial reporting term define rule af securities exchange act abbvie internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle unite states internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation report management assess effectiveness abbvie internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal control integrate framework framework base assessment management conclude abbvie maintain effective internal control financial reporting december base coso criterion abbvie acquire pharmacyclic inc pharmacyclic represent material change internal control financial reporting management assessment effectiveness management exclude pharmacyclic assessment conclusion effectiveness internal control financial reporting december abbvie consolidated balance sheet december include billion total asset exclude goodwill intangible asset include management assessment internal control financial report related pharmacyclic addition abbvie consolidated statement net earning include million net revenue reflect net loss million relate pharmacyclic effectiveness abbvie internal control financial reporting december audit ernst young llp independent register public accounting firm state attestation report appear hereof express unqualified opinion effectiveness abbvie internal control financial reporting december report independent register public accounting firm board director shareholders abbvie inc audit abbvie inc subsidiary internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework coso criteria abbvie inc subsidiary management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate indicate accompany management report internal control financial reporting management assessment conclusion effectiveness internal control financial reporting include internal control pharmacyclics inc acquire include consolidated financial statement abbvie inc subsidiary constitute billion total asset exclude goodwill intangible asset include management assessment conclusion effectiveness internal control financial reporting december million million revenue net loss respectively year end audit internal control financial reporting abbvie inc subsidiary include evaluation internal control financial reporting pharmacyclics inc opinion abbvie inc subsidiary maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated balance sheet december relate consolidated statement earning comprehensive income equity cash flow year period end december abbvie inc subsidiary report date february express unqualified opinion thereon ernst young llp chicago illinois february iii item director executive officer corporate governance incorporate reference information concern director nominee board director committeescommittee board director section beneficial ownership report compliance procedure recommendation nomination director transaction business annual meeting include abbvie inc proxy statement definitive proxy statement file march incorporate reference text find caption executive officer registrant page hereof abbvie code business conduct require business activity conduct compliance applicable law regulation ethical principle value director officer employee abbvie require read understand abide requirement code business conduct applicable abbvie code business conduct available corporate governance section abbvie investor relation website wwwabbvieinvestorcom waiver code business conduct director executive officer abbvie audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller person perform similar function website business day follow date amendment waiver addition abbvie disclose waiver code business conduct executive officer director website abbvie chief ethic compliance officer report chief executive officer public policy committee chief ethic compliance officer responsible overseeing administer monitor abbvie compliance program item executive compensation material include proxy statement heading director compensation executive compensation compensation committee report incorporate reference definitive proxy statement file march item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information follow table present information december abbvie equity compensation plan abbvie common stock authorize issuance c number security remain available number b future security weight issuance average equity issue exercise compensation exercise price plan outstanding outstanding exclude option option security warrant warrant reflect plan category right right column equity compensation plan approve security holder equity compensation plan approve security holder total include share issuable abbvie incentive stock program pursuant award grant abbott adjust abbvie award connection abbvie separation abbott weightedaverage exercise price include outstanding restricted stock unit restrict stock award exercise price b information concern security ownership incorporate reference material head security ownership security ownership executive officer director proxy statement definitive proxy statement file march item certain relationship relate transaction director independence material include proxy statement heading board director committee corporate governance material procedure approval related person transaction incorporate reference definitive proxy statement file march item principal accounting fee service material include proxy statement heading audit fee nonaudit fee policy audit committee preapproval audit permissible nonaudit services independent register public accounting firm incorporate reference definitive proxy statement file march iv item